fluorouracil and Peripheral Nervous System Diseases
fluorouracil has been researched along with Peripheral Nervous System Diseases in 130 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Peripheral Nervous System Diseases: Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"The study investigated the potential prophylactic effect of L-carnosine against acute oxaliplatin neurotoxicity in colorectal cancer patients with emphasis on the redox (Nrf-2, MDA), inflammatory (NF-κB, TNF-α), and apoptotic (caspase-3) parameters." | 9.30 | L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways. ( El Abhar, H; Saad, AS; Saleh, S; Schaalan, M; Yehia, R, 2019) |
"Metformin may be a promising drug in protecting colorectal cancer patients against oxaliplatin-induced chronic peripheral sensory neuropathy." | 9.27 | Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study. ( El-Fatatry, BM; Hussien, FZ; Ibrahim, OM; Mostafa, TM, 2018) |
"Ixabepilone plus capecitabine demonstrated a clear activity and an acceptable safety profile in Chinese patients with anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer, and the majority of patients completed 6 cycles of the therapy with manageable neuropathy toxicities." | 9.14 | Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment. ( Fan, Y; Wang, J; Xu, B, 2010) |
"The addition of capecitabine to docetaxel significantly improves overall survival in anthracycline-pretreated metastatic breast cancer." | 9.14 | Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results. ( Gennatas, K; Gennatas, S; Michalaki, V, 2009) |
"We sought to determine whether the combination of ixabepilone plus capecitabine improved overall survival (OS) compared with capecitabine alone in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes." | 9.14 | Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. ( Conte, P; Da Costa, SC; Manikhas, A; Medina, C; Peck, R; Perez Manga, G; Poulart, V; Rixe, O; Ro, J; Rondinon, M; Rubio, G; Sparano, JA; Vrdoljak, E; Xu, B, 2010) |
" This phase I/II trial was carried out to evaluate the combination of capecitabine and the proteasome inhibitor bortezomib in anthracycline and/or taxane-pretreated patients with metastatic breast cancer." | 9.13 | A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. ( Brossart, P; Freier, W; Greil, R; Kiewe, P; Kühnhardt, D; Kümmel, S; Lange, W; Lehenbauer-Dehm, S; Niederle, N; Possinger, K; Preiss, J; Regierer, A; Schippinger, W; Schmid, P; Van de Velde, H, 2008) |
"COX-2 activation may mediate capecitabine induced toxicities, eg, hand-foot syndrome (HFS) and colorectal cancer progression, both of which may be improved by concurrent celecoxib." | 9.12 | Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? ( Ayers, GD; Brown, T; Crane, CC; Curley, SA; Delcos, M; Feig, B; Janjan, N; Lin, EH; Morris, J; Rodriguez-Bigas, MA; Ross, A; Skibber, J; Vadhan, SR, 2006) |
"This study evaluated the toxicity and efficacy of docetaxel/capecitabine as neoadjuvant treatment for stage 2/3 breast cancer." | 9.11 | A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. ( Berman, A; Chow, CK; Danforth, D; Eng-Wong, J; Lebowitz, PF; Liu, E; Merino, MJ; Swain, SM; Venzon, D; Zia, F; Zujewski, J, 2004) |
"The effectiveness of capecitabine, an oral fluoropyrimidine carbamate, is well documented in previously untreated metastatic colorectal cancer patients (overall response rate: 25%)." | 9.11 | Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. ( Bang, YJ; Heo, DS; Joh, YH; Kim, DW; Kim, NK; Kim, TM; Kim, TY; Kwon, JH; Lee, JJ; Oh, DY; Yu, SJ, 2004) |
"FOLFOX, a bimonthly combination of leucovorin, 5-fluorouracil and oxaliplatin, is active in metastatic colorectal cancer, but sometimes causes cumulative sensory neurotoxicity." | 9.11 | Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C, 2004) |
"Docetaxel and capecitabine, a tumor-activated oral fluoropyrimidine, show high single-agent efficacy in metastatic breast cancer (MBC) and synergy in preclinical studies." | 9.10 | Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. ( Ayoub, JP; Cervantes, G; Fumoleau, P; Jones, S; Leonard, R; Lui, WY; Mauriac, L; Miles, D; Moiseyenko, V; O'Shaughnessy, J; Twelves, C; Van Hazel, G; Verma, S; Vukelja, S, 2002) |
"Oral capecitabine was evaluated in terms of overall response rate, safety, and tolerability as first-line therapy in women aged > or = 55 years with advanced/metastatic breast cancer." | 9.09 | Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. ( Bell, D; Blum, J; Burger, HU; Jones, SE; Laws, S; Mauriac, L; Miles, D; Moiseyenko, V; Oshaughnessy, JA; Osterwalder, B; Rosso, R, 2001) |
"To identify the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of oxaliplatin (L-OHP) given on a weekly schedule including fixed doses of leucovorin (LV) and infusional 5-fluorouracil (5-FU), to define the toxicity profile of this regimen and to find preliminary evidence of its activity in pretreated patients with metastatic colorectal cancer (MCRC)." | 9.09 | Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer. ( Manzione, L; Pizza, C; Rosati, G; Rossi, A; Tucci, A, 2001) |
"A 66-year-old woman with metastatic mammary carcinoma, who was being treated with capecitabine, contracted a herpes zoster infection that was treated with the antiviral drug brivudin." | 8.86 | Interaction between capecitabine and brivudin in a patient with breast cancer. ( Baena-Cañada, JM; García-Olmedo, O; Jiménez-Bárcenas, R; Martínez, MJ; Muriel-Cueto, P, 2010) |
" Ixabepilone is approved by the FDA for treatment of patients with metastatic breast cancer (MBC) progressing after taxanes and anthracyclines, either in combination with capecitabine or as monotherapy if the patient has already progressed on capecitabine." | 8.86 | Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer. ( Egerton, N, 2010) |
"To review available data and implications for nurses of combination regimens containing capecitabine for metastatic breast cancer." | 8.85 | Capecitabine-based combination therapy for breast cancer: implications for nurses. ( Frye, DK, 2009) |
"This article reviews the preclinical and clinical data on ixabepilone in patients with locally advanced and metastatic breast cancer (MBC) and provides guidance for pharmacists on its optimal use." | 8.85 | The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer. ( Boehnke Michaud, L, 2009) |
"The combination of capecitabine (Xeloda) and oxaliplatin (Eloxatin), or XELOX, is an effective and safe approach to the treatment of advanced colorectal cancer, with the potential advantage of convenience over standard combination regimens." | 8.81 | Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer? ( Twelves, C, 2002) |
"When the 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy regimen is used to treat colorectal cancer (CRC), chemotherapy-induced peripheral neuropathy (CIPN) caused by oxaliplatin can substantially affect quality of life (QOL) in the CRC patients." | 7.96 | Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: A cross-sectional study. ( Chen, JL; Chou, PL; Hsu, HT; Huang, YY; Juan, CH; Lin, PC; Wu, LM, 2020) |
" For practical reasons and for the convenience of the patient, we used XELOX (Xeloda 2000 mg/m2 orally on days 1-14 and oxaliplatin 130 mg/m2 as a 30-min infusion on day 1) in patients with advanced colorectal cancer resistant to irinotecan and 5-fluorouracil." | 7.72 | Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer. ( Hahn, P; Jensen, HA; Pfeiffer, P, 2003) |
" We undertook a retrospective study comparing the incidences of hand-foot syndrome in 67 patients with metastatic colorectal cancer who took capecitabine (Xeloda) with or without celecoxib." | 7.71 | Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. ( Ayers, GD; Lin, E; Morris, JS, 2002) |
" Severe taxane-related toxic effects were more frequent in group A, while severe thrombocytopenia was low and present only in group A." | 6.73 | Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. ( Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N, 2008) |
"Patients with colorectal cancer (CRC) and liver metastases have a poor prognosis, but can benefit from perioperative chemotherapy and disease resection." | 6.73 | Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. ( Gruenberger, B; Gruenberger, T; Herbst, F; Scheithauer, W; Schueller, J; Tamandl, D; Zielinski, C, 2008) |
" We weekly applied the orofacial section of the Acute and Chronic Neuropathy Questionnaire of Common Toxicity Criteria for Adverse Events of the National Cancer Institute of the United States of America (Oxaliplatin-specific neurotoxicity scale)." | 5.56 | FLOX (5-fluorouracil + leucovorin + oxaliplatin) chemotherapy for colorectal cancer leads to long-term orofacial neurotoxicity: a STROBE-guided longitudinal prospective study. ( Costa, BA; da Rocha Filho, DR; de Albuquerque Ribeiro Gondinho, P; de Barros Silva, PG; Gifoni, MAC; Junior, RCPL; Lima, MVA; Lisboa, MRP; Vale, ML, 2020) |
"Platinum was readily detectable in skin biopsies more than 60 months post-completion of FOLFOX." | 5.51 | Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy. ( Cao, Y; Chang, Q; Chen, EX; Hedley, D; Ornatsky, O; Zhang, W, 2019) |
"Twenty-eight colorectal cancer patients who received infusional 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) therapy were randomly and evenly assigned to the cystine and theanine group and the control group." | 5.34 | Protective effect of the oral administration of cystine and theanine on oxaliplatin-induced peripheral neuropathy: a pilot randomized trial. ( Abe, T; Akazawa, N; Hirashima, T; Ichikawa, H; Kakita, T; Kobayashi, M; Komura, T; Oikawa, M; Okada, T; Otake, S; Sato, R; Tsuchiya, T; Yazawa, T, 2020) |
"Fluorouracil (5-FU), leucovorin (LV) and oxaliplatin (FOLFOX) plus panitumumab therapy is a commonly used first-line chemotherapy for metastatic colorectal cancer (mCRC)." | 5.30 | SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer. ( Fukunaga, M; Kato, T; Kotaka, M; Kuramochi, H; Kuroda, H; Kurosawa, S; Minagawa, N; Mishima, H; Miura, T; Miwa, K; Munemoto, Y; Nagata, N; Nakamura, M; Noura, S; Oba, K; Sakamoto, J; Satake, H; Takahashi, M; Takahashi, T; Touyama, T, 2019) |
"The study investigated the potential prophylactic effect of L-carnosine against acute oxaliplatin neurotoxicity in colorectal cancer patients with emphasis on the redox (Nrf-2, MDA), inflammatory (NF-κB, TNF-α), and apoptotic (caspase-3) parameters." | 5.30 | L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways. ( El Abhar, H; Saad, AS; Saleh, S; Schaalan, M; Yehia, R, 2019) |
"Metformin may be a promising drug in protecting colorectal cancer patients against oxaliplatin-induced chronic peripheral sensory neuropathy." | 5.27 | Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study. ( El-Fatatry, BM; Hussien, FZ; Ibrahim, OM; Mostafa, TM, 2018) |
" Patients aged 18 years or older with high-risk stage II and stage III colorectal cancer underwent central randomisation with minimisation for centre, choice of regimen, sex, disease site, N stage, T stage, and the starting dose of capecitabine." | 5.27 | 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. ( Allan, K; Azzabi, A; Boyd, KA; Bridgewater, J; Briggs, A; Cassidy, J; Cunningham, D; Dhadda, AS; Ellis, R; Essapen, S; Falk, S; Farrugia, D; Glimelius, B; Gollins, S; Harkin, A; Harrison, M; Haydon, A; Hickish, T; Hollander, NH; Iveson, TJ; Kerr, RS; McQueen, J; Medley, L; Olesen, RK; Paul, J; Propper, D; Raouf, S; Rees, C; Saunders, MP; Scudder, C; Tabernero, J; Wasan, HS; Waterston, A; Weaver, A; Webb, A; Wilson, C, 2018) |
" We therefore conducted a multicenter randomized phase III trial to compare fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) with and without Goshajinkigan (GJG), a traditional Japanese herbal medicine (Kampo), to determine GJG's potential for reducing peripheral neuropathy in patients with colorectal cancer." | 5.20 | Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. ( Baba, H; Emi, Y; Higashijima, J; Ishida, H; Kakeji, Y; Kato, T; Kojima, H; Kon, M; Kono, T; Maehara, Y; Miyake, Y; Ogata, Y; Oki, E; Saeki, H; Sakaguchi, Y; Shirabe, K; Takahashi, K; Tomita, N; Yamanaka, T, 2015) |
"Infusional 5-fluorouracil and leucovorin with oxaliplatin is one of the standard regimens for patients with pretreated metastatic colorectal cancer, as well as for first-line chemotherapy." | 5.15 | A multicenter phase-II study of 5-FU, leucovorin and oxaliplatin (FOLFOX6) in patients with pretreated metastatic colorectal cancer. ( Esaki, T; Fujii, H; Inaba, Y; Kato, K; Kusaba, H; Mizuno, T; Mizunuma, N; Muro, K; Shimada, Y; Shirao, K; Tsuji, Y; Yoshioka, A, 2011) |
"The addition of capecitabine to docetaxel significantly improves overall survival in anthracycline-pretreated metastatic breast cancer." | 5.14 | Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results. ( Gennatas, K; Gennatas, S; Michalaki, V, 2009) |
"Oxaliplatin is a promising drug for cancer therapy and the oxaliplatin/5-fluorouracil/leucovorin (FOLFOX) regimen has become the standard adjuvant treatment for colorectal cancer." | 5.14 | Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. ( Airoldi, M; Cattel, L; Drescher, A; Jaehde, U; Milla, P; Weber, G, 2009) |
"We sought to determine whether the combination of ixabepilone plus capecitabine improved overall survival (OS) compared with capecitabine alone in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes." | 5.14 | Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. ( Conte, P; Da Costa, SC; Manikhas, A; Medina, C; Peck, R; Perez Manga, G; Poulart, V; Rixe, O; Ro, J; Rondinon, M; Rubio, G; Sparano, JA; Vrdoljak, E; Xu, B, 2010) |
"Ixabepilone plus capecitabine demonstrated a clear activity and an acceptable safety profile in Chinese patients with anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer, and the majority of patients completed 6 cycles of the therapy with manageable neuropathy toxicities." | 5.14 | Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment. ( Fan, Y; Wang, J; Xu, B, 2010) |
" This phase I/II trial was carried out to evaluate the combination of capecitabine and the proteasome inhibitor bortezomib in anthracycline and/or taxane-pretreated patients with metastatic breast cancer." | 5.13 | A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. ( Brossart, P; Freier, W; Greil, R; Kiewe, P; Kühnhardt, D; Kümmel, S; Lange, W; Lehenbauer-Dehm, S; Niederle, N; Possinger, K; Preiss, J; Regierer, A; Schippinger, W; Schmid, P; Van de Velde, H, 2008) |
"COX-2 activation may mediate capecitabine induced toxicities, eg, hand-foot syndrome (HFS) and colorectal cancer progression, both of which may be improved by concurrent celecoxib." | 5.12 | Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? ( Ayers, GD; Brown, T; Crane, CC; Curley, SA; Delcos, M; Feig, B; Janjan, N; Lin, EH; Morris, J; Rodriguez-Bigas, MA; Ross, A; Skibber, J; Vadhan, SR, 2006) |
"This study evaluated the toxicity and efficacy of docetaxel/capecitabine as neoadjuvant treatment for stage 2/3 breast cancer." | 5.11 | A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. ( Berman, A; Chow, CK; Danforth, D; Eng-Wong, J; Lebowitz, PF; Liu, E; Merino, MJ; Swain, SM; Venzon, D; Zia, F; Zujewski, J, 2004) |
"FOLFOX, a bimonthly combination of leucovorin, 5-fluorouracil and oxaliplatin, is active in metastatic colorectal cancer, but sometimes causes cumulative sensory neurotoxicity." | 5.11 | Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C, 2004) |
"The effectiveness of capecitabine, an oral fluoropyrimidine carbamate, is well documented in previously untreated metastatic colorectal cancer patients (overall response rate: 25%)." | 5.11 | Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. ( Bang, YJ; Heo, DS; Joh, YH; Kim, DW; Kim, NK; Kim, TM; Kim, TY; Kwon, JH; Lee, JJ; Oh, DY; Yu, SJ, 2004) |
"Docetaxel and capecitabine, a tumor-activated oral fluoropyrimidine, show high single-agent efficacy in metastatic breast cancer (MBC) and synergy in preclinical studies." | 5.10 | Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. ( Ayoub, JP; Cervantes, G; Fumoleau, P; Jones, S; Leonard, R; Lui, WY; Mauriac, L; Miles, D; Moiseyenko, V; O'Shaughnessy, J; Twelves, C; Van Hazel, G; Verma, S; Vukelja, S, 2002) |
"Diarrhea is dose-limiting with weekly 5-fluorouracil (5-FU) plus high-dose leucovorin (LV)." | 5.09 | Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant. ( Blumenson, LE; Creaven, PJ; Frank, C; Meropol, NJ; Rustum, YM, 1999) |
"Oral capecitabine was evaluated in terms of overall response rate, safety, and tolerability as first-line therapy in women aged > or = 55 years with advanced/metastatic breast cancer." | 5.09 | Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. ( Bell, D; Blum, J; Burger, HU; Jones, SE; Laws, S; Mauriac, L; Miles, D; Moiseyenko, V; Oshaughnessy, JA; Osterwalder, B; Rosso, R, 2001) |
"To identify the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of oxaliplatin (L-OHP) given on a weekly schedule including fixed doses of leucovorin (LV) and infusional 5-fluorouracil (5-FU), to define the toxicity profile of this regimen and to find preliminary evidence of its activity in pretreated patients with metastatic colorectal cancer (MCRC)." | 5.09 | Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer. ( Manzione, L; Pizza, C; Rosati, G; Rossi, A; Tucci, A, 2001) |
" All included patients who were treated for colorectal cancer, mainly with oxaliplatin in combination with 5-fluorouracil/leucovorin." | 4.90 | A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. ( Beijers, AJ; Mols, F; Vreugdenhil, G, 2014) |
" Ixabepilone is approved by the FDA for treatment of patients with metastatic breast cancer (MBC) progressing after taxanes and anthracyclines, either in combination with capecitabine or as monotherapy if the patient has already progressed on capecitabine." | 4.86 | Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer. ( Egerton, N, 2010) |
"A 66-year-old woman with metastatic mammary carcinoma, who was being treated with capecitabine, contracted a herpes zoster infection that was treated with the antiviral drug brivudin." | 4.86 | Interaction between capecitabine and brivudin in a patient with breast cancer. ( Baena-Cañada, JM; García-Olmedo, O; Jiménez-Bárcenas, R; Martínez, MJ; Muriel-Cueto, P, 2010) |
"This article reviews the preclinical and clinical data on ixabepilone in patients with locally advanced and metastatic breast cancer (MBC) and provides guidance for pharmacists on its optimal use." | 4.85 | The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer. ( Boehnke Michaud, L, 2009) |
"To review available data and implications for nurses of combination regimens containing capecitabine for metastatic breast cancer." | 4.85 | Capecitabine-based combination therapy for breast cancer: implications for nurses. ( Frye, DK, 2009) |
"The combination of capecitabine (Xeloda) and oxaliplatin (Eloxatin), or XELOX, is an effective and safe approach to the treatment of advanced colorectal cancer, with the potential advantage of convenience over standard combination regimens." | 4.81 | Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer? ( Twelves, C, 2002) |
"When the 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy regimen is used to treat colorectal cancer (CRC), chemotherapy-induced peripheral neuropathy (CIPN) caused by oxaliplatin can substantially affect quality of life (QOL) in the CRC patients." | 3.96 | Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: A cross-sectional study. ( Chen, JL; Chou, PL; Hsu, HT; Huang, YY; Juan, CH; Lin, PC; Wu, LM, 2020) |
"Oxaliplatin, combined with capecitabine (CAPOX) or infused 5-fluorouracil (FOLFOX), is standard of care in the adjuvant treatment of colorectal cancer (CRC)." | 3.91 | Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy. ( Bono, P; Hänninen, UA; Karhunen, M; Lamminmäki, A; Osterlund, P; Soveri, LM, 2019) |
"Oxaliplatin in combination with infusional 5-fluorouracil/leucovorin (FOLFOX) have emerged as the standard of care in the therapy of advanced-stage colorectal cancer." | 3.74 | [Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions]. ( Akashi, T; Ando, H; Hanaoka, T; Itagaki, H; Kobayashi, Y; Muto, O; Ono, T; Onuki, M; Tanaka, Y, 2007) |
"Oxaliplatin in combination with infusional 5-fluorouracil/Leucovorin (FOLFOX) has emerged as the treatment of choice for advanced-stage colorectal cancer." | 3.74 | [Reduction of oxaliplatin-related neurotoxicity by Gosha-jinki-gan]. ( Hibino, M; Imano, H; Nakamura, M; Shindo, Y; Tenma, K; Yoshino, K, 2008) |
" For practical reasons and for the convenience of the patient, we used XELOX (Xeloda 2000 mg/m2 orally on days 1-14 and oxaliplatin 130 mg/m2 as a 30-min infusion on day 1) in patients with advanced colorectal cancer resistant to irinotecan and 5-fluorouracil." | 3.72 | Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer. ( Hahn, P; Jensen, HA; Pfeiffer, P, 2003) |
" We undertook a retrospective study comparing the incidences of hand-foot syndrome in 67 patients with metastatic colorectal cancer who took capecitabine (Xeloda) with or without celecoxib." | 3.71 | Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. ( Ayers, GD; Lin, E; Morris, JS, 2002) |
" This prospective cohort study investigated orofacial complications of combination chemotherapy (cyclophosphamide, methotrexate, fluorouracil, vincristine, and prednisone) in women with breast cancer." | 3.68 | Orofacial complications of chemotherapy for breast cancer. ( McCarthy, GM; Skillings, JR, 1992) |
"Chemotherapy in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy is under debate." | 2.94 | Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study). ( Fukunaga, M; Ide, Y; Ikumoto, T; Iwamoto, S; Kanazawa, A; Kato, T; Konishi, K; Kotaka, M; Kudo, T; Kurata, T; Sakai, D; Sano, Y; Satake, H; Satoh, T; Sugimoto, N; Tomita, N; Tsuji, A; Yamanaka, T, 2020) |
" The secondary endpoints were chronic cumulative neurotoxicity (EORTC QLQ-CIPN20), time to grade 2 neurotoxicity (NCI-CTCAE or the oxaliplatin-specific neuropathy scale), acute neurotoxicity (analog scale), rates of dose reduction or withdrawal due to OIPN, 3-year disease-free survival (DFS) and adverse events." | 2.94 | Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer. ( Chen, G; Deng, YH; Ding, PR; Fan, WH; Feng, F; Jin, Y; Li, YH; Liang, HL; Lu, ZH; Peng, JW; Ren, C; Shi, SM; Wang, DS; Wang, F; Wang, FH; Wang, W; Wang, ZQ; Xie, CB; Xu, RH; Zhang, JW, 2020) |
"There were no statistically significant neuropathy differences among the study arms as measured by the primary end point or additional measures of neuropathy, including clinician-determined measurement of the time to grade 2 neuropathy by using the National Cancer Institute Common Terminology Criteria for Adverse Events scale or an oxaliplatin-specific neuropathy scale." | 2.79 | Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). ( Atherton, P; Dakhil, SR; Fehrenbacher, L; Flynn, KA; Grothey, A; Lewis, GC; Loprinzi, CL; Qamar, R; Qin, R; Seisler, D, 2014) |
"To establish a safe regimen of high-dose regional chemotherapy with NIPP using cisplatin in patients with incurable rectal cancer." | 2.79 | Negative-balance isolated pelvic perfusion in patients with incurable symptomatic rectal cancer: results and drug dose correlation to adverse events. ( Kim, C; Kimata, R; Kumita, S; Murata, S; Onozawa, S; Tajima, H; Uchida, E, 2014) |
" The severity of OPN was assessed according to the Common Toxicity Criteria for Adverse Events at baseline, every 2 weeks until the 8th cycle, and every 4 weeks thereafter until the 26th week." | 2.78 | Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy. ( Fukunaga, M; Hata, T; Kojima, H; Kono, T; Matsui, T; Mishima, H; Morita, S; Munemoto, Y; Nagata, N; Sakamoto, J; Shimada, M; Takemoto, H, 2013) |
" This study was to investigate the efficacy and safety of oxaliplatin in combination with capecitabine as first-line chemotherapy for AGC patients." | 2.74 | [Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer]. ( Dong, NN; Liu, ZF; Wang, MY; Zhang, Q, 2009) |
"The aim of the study was to assess the toxicity and the clinical activity of biweekly oxaliplatin (OXA) in combination with continuous infusional 5-fluorouracil (5-FU) and leucovorin (LV) administered every 2 weeks (modified FOLFOX-4 regimen) in elderly patients with advanced gastric cancer (AGC)." | 2.73 | Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer. ( Fu, Z; Guan, F; Guo, QS; Liu, ZF; Wang, MY; Yang, XG; Zhang, XQ, 2008) |
" Severe taxane-related toxic effects were more frequent in group A, while severe thrombocytopenia was low and present only in group A." | 2.73 | Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. ( Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N, 2008) |
"Patients with colorectal cancer (CRC) and liver metastases have a poor prognosis, but can benefit from perioperative chemotherapy and disease resection." | 2.73 | Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. ( Gruenberger, B; Gruenberger, T; Herbst, F; Scheithauer, W; Schueller, J; Tamandl, D; Zielinski, C, 2008) |
"Neurotoxicity was recorded for all patients using standard adverse event reporting." | 2.73 | Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. ( Bearden, JD; Cecchini, RS; Cella, D; Colangelo, LH; Colman, LK; Costantino, JP; Ganz, PA; Kopec, JA; Kuebler, JP; Land, SR; Lanier, KS; Murphy, K; Needles, BM; O'Connell, MJ; Pajon, ER; Seay, TE; Smith, RE; Wieand, HS; Wolmark, N, 2007) |
" Pharmacokinetic and neurotoxicity assessments were performed at the cohort 2 MTD." | 2.71 | Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. ( Adjei, AA; Ames, MM; Atherton, P; Erlichman, C; Galanis, E; Goetz, MP; Goldberg, RM; Pitot, H; Reid, JM; Rubin, J; Sloan, JA; Windebank, AJ, 2003) |
" In 10 of 19 patients who had not responded (SD, PD), three additional courses of chemotherapy were combined with sCMT (with 25 sCMT applications)." | 2.71 | Whole-body hyperthermia in the scope of von Ardenne's systemic cancer multistep therapy (sCMT) combined with chemotherapy in patients with metastatic colorectal cancer: a phase I/II study. ( Ahlers, O; Deja, M; Dräger, J; Felix, R; Hildebrandt, B; Kerner, T; Löffel, J; Riess, H; Stroszczynski, C; Wust, P, 2004) |
"Grade 2/3 neutropenia was observed in 4 (3%) treatment cycles." | 2.71 | Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors. ( Agelaki, S; Amarantidis, K; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Xenidis, N, 2004) |
" Pharmacokinetic parameters of capecitabine and its metabolites (5'-deoxy-5-fluorouridine, 5-fluorouracil and alpha-fluoro-beta-alanine) were similar to those reported by other authors." | 2.70 | Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics. ( Budd, GT; Bukowski, R; Chang, DZ; Ganapathi, R; Olencki, T; Osterwalder, B; Peereboom, D, 2001) |
"Fifty-seven Dukes C colorectal cancer patients were given 5-fluorouracil-interferon-alpha 2b adjuvant treatment from October 1986 to September 1990." | 2.67 | 5-Fluorouracil-interferon-alpha 2b adjuvant treatment of Dukes C colorectal cancer. ( Cremone, L; Espinosa, A; Faiella, F; Frasci, G; Leone, F; Monaco, M; Persico, G; Sapio, U, 1994) |
"Patterns of breast cancer care continue to be amended because of the more frequent use of anthracyclines and taxanes in earlier lines of therapy (particularly in the adjuvant setting) and the emergence of multidrug resistance." | 2.46 | Ixabepilone. ( Stein, A, 2010) |
"Oxaliplatin utilized in colorectal neoplasms treatment could induce acute peripheral neuropathy (APN) which is a dreadful and frequent adverse event." | 1.91 | Incidence and risk factors associated with development of oxalipatin-induced acute peripheral neuropathy in colorectal cancer patients. ( Ben Ayed, W; Ben Mahmoud, IT; Ben Said, A; Berguiga, S; Cherif, I; Hamdi, A; Houij, R; Limayem, I, 2023) |
"The prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel (GnP))." | 1.62 | Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients. ( Asama, H; Hashimoto, M; Hikichi, T; Irie, H; Kato, T; Kobashi, R; Konno, N; Nakamura, J; Ohira, H; Okubo, Y; Sato, Y; Sugimoto, M; Suzuki, R; Takagi, T; Takasumi, M, 2021) |
"By using the Korean Pancreatic Cancer (K-PaC) registry, we compared the clinical outcomes of FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GNP) in patients with metastatic pancreatic cancer (MPC)." | 1.56 | Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry. ( Cha, HS; Hwang, JH; Kim, J; Kim, JW; Kim, MJ; Lee, JC; Lee, WJ; Park, P; Shin, DW; Woo, SM; Yang, SY, 2020) |
" We weekly applied the orofacial section of the Acute and Chronic Neuropathy Questionnaire of Common Toxicity Criteria for Adverse Events of the National Cancer Institute of the United States of America (Oxaliplatin-specific neurotoxicity scale)." | 1.56 | FLOX (5-fluorouracil + leucovorin + oxaliplatin) chemotherapy for colorectal cancer leads to long-term orofacial neurotoxicity: a STROBE-guided longitudinal prospective study. ( Costa, BA; da Rocha Filho, DR; de Albuquerque Ribeiro Gondinho, P; de Barros Silva, PG; Gifoni, MAC; Junior, RCPL; Lima, MVA; Lisboa, MRP; Vale, ML, 2020) |
"Platinum was readily detectable in skin biopsies more than 60 months post-completion of FOLFOX." | 1.51 | Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy. ( Cao, Y; Chang, Q; Chen, EX; Hedley, D; Ornatsky, O; Zhang, W, 2019) |
" Neurological adverse effects were assessed by CTC v2." | 1.51 | Effect of diabetes on neurological adverse effects and chemotherapy induced peripheral neuropathy in advanced colorectal cancer patients treated with different FOLFOX regimens. ( Bano, N; Ikram, R, 2019) |
"Thirteen patients with metastatic pancreatic cancer underwent clinical, sonographic, and electrophysiological evaluation before, 3 and 7 months after treatment with 12 two-week cycles of FOLFIRINOX." | 1.51 | Prospective Study of the Clinical, Electrophysiologic, and Sonographic Characteristics of Oxaliplatin-Induced Neuropathy. ( Fisse, AL; Gold, R; Höffken, N; Lönneker, N; Pitarokoili, K; Reinacher-Schick, A; Trampe, N; Yoon, MS, 2019) |
"Forty-seven cases of stage III colorectal cancer who received adjuvant chemotherapy with oxaliplatin after curative surgery between January 2010 and August 2014 were retrospectively reviewed." | 1.46 | Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy. ( Horiuchi, T; Kimura, M; Maeda, T; Shirai, Y; Tanishima, H; Tominaga, T, 2017) |
" By exclusion the pseudo-obstruction was attributed to a toxic oxaliplatin-induced autonomic neuropathy which slowly improved during months of follow-up." | 1.42 | A case of delayed oxaliplatin-induced pseudo-obstruction: an atypical presentation of oxaliplatin neurotoxicity. ( Bleecker, JD; Pauwels, W; Vandamme, M, 2015) |
"Participants were 91 colorectal cancer patients treated with OXA-based chemotherapy." | 1.40 | Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. ( Alberti, P; Argyriou, AA; Bergamo, F; Briani, C; Bruna, J; Cacciavillani, M; Campagnolo, M; Cavaletti, G; Cazzaniga, M; Cortinovis, D; Frigeni, B; Izquierdo, C; Kalofonos, HP; Velasco, R, 2014) |
"Patients with colorectal cancer who received adjuvant CAPOX from January 2005 to August 2011 were reviewed." | 1.40 | Incidence of cold-induced peripheral neuropathy and dose modification of adjuvant oxaliplatin-based chemotherapy for patients with colorectal cancer. ( Altaf, R; Kristensen, B; Lund Brixen, A; Nielsen, SE, 2014) |
"We retrospectively investigated the frequency and severity of adverse events in 124 patients with colorectal cancer who were treated by mFOLFOX6 regimen from August, 2005 to December, 2006." | 1.35 | [Revision of the informed consent form for patients based on investigation of adverse events of mFOLFOX6 regimen]. ( Boku, N; Kato, T; Kimura, H; Kudou, Y; Matsunaga, Y; Motokawa, S; Muramatsu, T; Nagata, N; Nakagaki, S; Ohashi, Y; Shino, M; Yamazaki, K; Yoshida, T, 2009) |
"The standard adjuvant therapy for rectal cancer is 5-fluorouracil (5-FU) often combined with radiotherapy." | 1.35 | A case of 5-fluorouracil-induced peripheral neuropathy. ( De Bleecker, JL; Pauwels, WJ; Werbrouck, BF, 2008) |
"Patients who had rectal cancer with a distal margin within 6 cm of the anal verge had the anus included in the field of radiotherapy (Group A, n = 26)." | 1.33 | Preoperative chemoradiation for rectal cancer causes prolonged pudendal nerve terminal motor latency. ( Chao, MW; Gibbs, P; Hiscock, R; Lim, JF; Tjandra, JJ, 2006) |
"Capecitabine (CAP) is a pro-drug of 5-FU and peripheral neuropathy associated with CAP has not been reported." | 1.32 | Peripheral neuropathy associated with capecitabine. ( Diasio, RB; McGee, PJ; Saif, MW; Wood, TE, 2004) |
"Carbamazepine levels were 4." | 1.31 | [Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study]. ( Adelsberger, H; Eckel, F; Erdmann, J; Lersch, C; Quasthoff, S; Schmelz, R, 2002) |
"Carbamazepine therapy was tried in 12 additional patients to determine whether the neurologic effects might be relieved." | 1.31 | Acute oxaliplatin-induced peripheral nerve hyperexcitability. ( Floeter, MK; Grem, JL; Lehky, T; Quinn, MG; Thomas, RR; Wilson, RH, 2002) |
"For locally advanced primary colorectal cancer, our institution has combined intraoperative electron irradiation (IOERT) with external beam irradiation (EBRT) +/- 5-fluorouracil (5-FU) and surgical resection." | 1.30 | Locally advanced primary colorectal cancer: intraoperative electron and external beam irradiation +/- 5-FU. ( Cha, S; Devine, R; Dozois, R; Fieck, JM; Gunderson, LL; Haddock, M; Martenson, JA; Nelson, H; O'Connell, MJ; Wolff, B, 1997) |
"Effect of this treatment on the pain could be evaluated in 16 patients." | 1.27 | Palliation of pelvic recurrence of colorectal cancer with intra-arterial 5-fluorouracil and mitomycin. ( Chuang, VP; Claghorn, L; Mavligit, G; Patt, YZ; Peters, RE; Wallace, S, 1985) |
Research
Studies (130)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 5 (3.85) | 18.7374 |
1990's | 8 (6.15) | 18.2507 |
2000's | 47 (36.15) | 29.6817 |
2010's | 53 (40.77) | 24.3611 |
2020's | 17 (13.08) | 2.80 |
Authors
Authors | Studies |
---|---|
Sugimoto, M | 1 |
Takagi, T | 1 |
Suzuki, R | 1 |
Konno, N | 1 |
Asama, H | 1 |
Sato, Y | 2 |
Irie, H | 1 |
Okubo, Y | 1 |
Nakamura, J | 1 |
Takasumi, M | 1 |
Hashimoto, M | 1 |
Kato, T | 8 |
Kobashi, R | 1 |
Hikichi, T | 1 |
Ohira, H | 1 |
Ben Mahmoud, IT | 1 |
Ben Said, A | 1 |
Berguiga, S | 1 |
Houij, R | 1 |
Cherif, I | 1 |
Hamdi, A | 1 |
Ben Ayed, W | 1 |
Limayem, I | 1 |
Yoshino, T | 4 |
Oki, E | 3 |
Misumi, T | 1 |
Kotaka, M | 7 |
Manaka, D | 4 |
Eto, T | 2 |
Hasegawa, J | 5 |
Takagane, A | 4 |
Nakamura, M | 4 |
Munemoto, Y | 6 |
Nakamura, F | 1 |
Bando, H | 2 |
Taniguchi, H | 2 |
Sakamoto, Y | 1 |
Shiozawa, M | 2 |
Nishi, M | 1 |
Horiuchi, T | 2 |
Yamagishi, H | 1 |
Sakamoto, J | 5 |
Mizushima, T | 3 |
Ohtsu, A | 5 |
Mori, M | 2 |
Okamoto, K | 1 |
Nozawa, H | 1 |
Emoto, S | 1 |
Murono, K | 1 |
Sasaki, K | 1 |
Ishihara, S | 1 |
Takahashi, M | 1 |
Kuroda, H | 1 |
Minagawa, N | 1 |
Noura, S | 1 |
Fukunaga, M | 3 |
Kuramochi, H | 1 |
Touyama, T | 3 |
Takahashi, T | 1 |
Miwa, K | 1 |
Satake, H | 3 |
Kurosawa, S | 1 |
Miura, T | 1 |
Mishima, H | 2 |
Oba, K | 2 |
Nagata, N | 4 |
Yamanaka, T | 3 |
Takeuchi, S | 1 |
Gamoh, M | 1 |
Saji, S | 2 |
Maehara, Y | 3 |
Cao, Y | 1 |
Chang, Q | 1 |
Zhang, W | 1 |
Ornatsky, O | 1 |
Hedley, D | 1 |
Chen, EX | 1 |
Shinozaki, K | 3 |
Matsui, T | 3 |
Ishigure, K | 2 |
Inoue, K | 1 |
Ishikawa, H | 2 |
Ishida, H | 4 |
Ogata, Y | 2 |
Goto, K | 1 |
Wang, DS | 1 |
Wang, ZQ | 1 |
Chen, G | 1 |
Peng, JW | 1 |
Wang, W | 1 |
Deng, YH | 1 |
Wang, FH | 1 |
Zhang, JW | 1 |
Liang, HL | 1 |
Feng, F | 1 |
Xie, CB | 1 |
Ren, C | 1 |
Jin, Y | 1 |
Shi, SM | 1 |
Fan, WH | 1 |
Lu, ZH | 1 |
Ding, PR | 1 |
Wang, F | 1 |
Xu, RH | 1 |
Li, YH | 1 |
Hsu, HT | 1 |
Wu, LM | 1 |
Lin, PC | 1 |
Juan, CH | 1 |
Huang, YY | 1 |
Chou, PL | 1 |
Chen, JL | 1 |
Tanabe, Y | 1 |
Shiraishi, S | 1 |
Hashimoto, K | 1 |
Ikeda, K | 1 |
Nishizawa, D | 1 |
Shimomura, A | 1 |
Ozaki, Y | 1 |
Tamura, N | 1 |
Yunokawa, M | 1 |
Yonemori, K | 1 |
Takano, T | 1 |
Kawabata, H | 1 |
Tamura, K | 1 |
Fujiwara, Y | 1 |
Shimizu, C | 1 |
Iwamoto, S | 1 |
Sakai, D | 1 |
Kudo, T | 1 |
Konishi, K | 1 |
Ide, Y | 1 |
Ikumoto, T | 1 |
Tsuji, A | 2 |
Sano, Y | 1 |
Sugimoto, N | 1 |
Satoh, T | 1 |
Kanazawa, A | 1 |
Kurata, T | 1 |
Tomita, N | 2 |
Park, H | 1 |
Jin, RU | 1 |
Wang-Gillam, A | 1 |
Suresh, R | 1 |
Rigden, C | 1 |
Amin, M | 1 |
Tan, BR | 1 |
Pedersen, KS | 1 |
Lim, KH | 1 |
Trikalinos, NA | 1 |
Acharya, A | 1 |
Copsey, ML | 1 |
Navo, KA | 1 |
Morton, AE | 1 |
Gao, F | 1 |
Lockhart, AC | 1 |
Mashimo, K | 1 |
Fujiwara, D | 1 |
Hoshida, T | 1 |
Morimoto, N | 1 |
Noda, A | 1 |
Takeda, T | 1 |
Tsubaki, M | 2 |
Nishida, S | 1 |
Sakaguchi, K | 1 |
Kobayashi, M | 2 |
Sato, R | 1 |
Komura, T | 1 |
Ichikawa, H | 1 |
Hirashima, T | 1 |
Otake, S | 1 |
Akazawa, N | 1 |
Yazawa, T | 1 |
Abe, T | 1 |
Okada, T | 1 |
Kakita, T | 1 |
Oikawa, M | 1 |
Tsuchiya, T | 1 |
de Albuquerque Ribeiro Gondinho, P | 1 |
de Barros Silva, PG | 1 |
Lisboa, MRP | 1 |
Costa, BA | 1 |
da Rocha Filho, DR | 1 |
Gifoni, MAC | 1 |
Lima, MVA | 1 |
Junior, RCPL | 1 |
Vale, ML | 1 |
Lee, JC | 1 |
Woo, SM | 1 |
Shin, DW | 1 |
Kim, J | 2 |
Yang, SY | 1 |
Kim, MJ | 1 |
Kim, JW | 2 |
Lee, WJ | 1 |
Cha, HS | 1 |
Park, P | 1 |
Hwang, JH | 1 |
Saito, Y | 1 |
Makiyama, A | 1 |
Tsuji, Y | 2 |
Fujiwara, T | 1 |
Harihara, Y | 1 |
Kurihara, N | 1 |
Ando, M | 2 |
Kusakawa, G | 1 |
Sakai, T | 1 |
Uchida, Y | 1 |
Takamoto, M | 1 |
Kimoto, S | 1 |
Hyodo, I | 2 |
Miura, Y | 1 |
Yamazaki, K | 2 |
Hironaka, S | 1 |
Boku, N | 3 |
Muro, K | 3 |
Takeshita, E | 1 |
Ishibashi, K | 2 |
Koda, K | 1 |
Oda, N | 1 |
Yoshimatsu, K | 1 |
Oya, M | 1 |
Yamaguchi, S | 1 |
Nakajima, H | 1 |
Momma, T | 1 |
Maekawa, H | 1 |
Yamada, T | 1 |
Tanakaya, K | 1 |
Gui, Q | 1 |
Li, D | 1 |
Zhuge, Y | 1 |
Xu, C | 1 |
Ji, WB | 1 |
Hong, KD | 1 |
Kim, JS | 1 |
Joung, SY | 1 |
Um, JW | 1 |
Min, BW | 1 |
Kuriyama, A | 1 |
Endo, K | 1 |
Iveson, TJ | 1 |
Kerr, RS | 1 |
Saunders, MP | 1 |
Cassidy, J | 2 |
Hollander, NH | 1 |
Tabernero, J | 1 |
Haydon, A | 1 |
Glimelius, B | 1 |
Harkin, A | 1 |
Allan, K | 1 |
McQueen, J | 1 |
Scudder, C | 1 |
Boyd, KA | 1 |
Briggs, A | 1 |
Waterston, A | 1 |
Medley, L | 1 |
Wilson, C | 1 |
Ellis, R | 1 |
Essapen, S | 1 |
Dhadda, AS | 1 |
Harrison, M | 1 |
Falk, S | 1 |
Raouf, S | 1 |
Rees, C | 1 |
Olesen, RK | 1 |
Propper, D | 1 |
Bridgewater, J | 1 |
Azzabi, A | 1 |
Farrugia, D | 1 |
Webb, A | 1 |
Cunningham, D | 1 |
Hickish, T | 1 |
Weaver, A | 1 |
Gollins, S | 1 |
Wasan, HS | 1 |
Paul, J | 1 |
El-Fatatry, BM | 1 |
Ibrahim, OM | 1 |
Hussien, FZ | 1 |
Mostafa, TM | 1 |
Pitarokoili, K | 1 |
Höffken, N | 1 |
Lönneker, N | 1 |
Fisse, AL | 1 |
Trampe, N | 1 |
Gold, R | 1 |
Reinacher-Schick, A | 1 |
Yoon, MS | 1 |
Yehia, R | 1 |
Saleh, S | 1 |
El Abhar, H | 1 |
Saad, AS | 1 |
Schaalan, M | 1 |
Soveri, LM | 1 |
Lamminmäki, A | 1 |
Hänninen, UA | 1 |
Karhunen, M | 1 |
Bono, P | 1 |
Osterlund, P | 1 |
Bano, N | 1 |
Ikram, R | 1 |
Kadakia, KC | 1 |
Worrilow, WM | 1 |
Coley, H | 1 |
Salem, ME | 1 |
Nakae, S | 1 |
Mizojiri, G | 1 |
Fujikawa, M | 1 |
Ishida, J | 1 |
Yamamoto, M | 1 |
Harada, N | 1 |
Haji, S | 1 |
Toyoda, M | 1 |
Senzaki, H | 1 |
Chen, Y | 1 |
Sun, Y | 1 |
Liang, SB | 1 |
Zong, JF | 1 |
Li, WF | 1 |
Chen, M | 1 |
Chen, L | 1 |
Mao, YP | 1 |
Tang, LL | 1 |
Guo, Y | 1 |
Lin, AH | 1 |
Liu, MZ | 1 |
Ma, J | 1 |
Argyriou, AA | 3 |
Cavaletti, G | 2 |
Antonacopoulou, A | 1 |
Genazzani, AA | 1 |
Briani, C | 2 |
Bruna, J | 2 |
Terrazzino, S | 1 |
Velasco, R | 2 |
Alberti, P | 2 |
Campagnolo, M | 2 |
Lonardi, S | 1 |
Cortinovis, D | 2 |
Cazzaniga, M | 2 |
Santos, C | 1 |
Psaromyalou, A | 1 |
Angelopoulou, A | 1 |
Kalofonos, HP | 4 |
Murata, S | 1 |
Onozawa, S | 1 |
Kim, C | 1 |
Tajima, H | 1 |
Kimata, R | 1 |
Uchida, E | 1 |
Kumita, S | 1 |
Kono, T | 3 |
Hata, T | 1 |
Morita, S | 2 |
Kojima, H | 2 |
Takemoto, H | 1 |
Shimada, M | 2 |
Loprinzi, CL | 2 |
Qin, R | 2 |
Dakhil, SR | 1 |
Fehrenbacher, L | 1 |
Flynn, KA | 1 |
Atherton, P | 2 |
Seisler, D | 1 |
Qamar, R | 1 |
Lewis, GC | 1 |
Grothey, A | 2 |
Nagashima, M | 1 |
Ooshiro, M | 1 |
Moriyama, A | 1 |
Sugishita, Y | 1 |
Kadoya, K | 1 |
Sato, A | 1 |
Kitahara, T | 1 |
Takagi, R | 1 |
Urita, T | 1 |
Yoshida, Y | 1 |
Tanaka, H | 1 |
Oshiro, T | 1 |
Okazumi, S | 1 |
Katoh, R | 1 |
Beijers, AJ | 2 |
Mols, F | 2 |
Vreugdenhil, G | 2 |
Altaf, R | 1 |
Lund Brixen, A | 1 |
Kristensen, B | 1 |
Nielsen, SE | 1 |
Tjan-Heijnen, VC | 1 |
Faber, CG | 1 |
van de Poll-Franse, LV | 1 |
Vandamme, M | 1 |
Pauwels, W | 1 |
Bleecker, JD | 1 |
Izquierdo, C | 1 |
Frigeni, B | 1 |
Cacciavillani, M | 1 |
Bergamo, F | 1 |
Emi, Y | 1 |
Higashijima, J | 2 |
Miyake, Y | 1 |
Kon, M | 1 |
Takahashi, K | 1 |
Saeki, H | 1 |
Sakaguchi, Y | 1 |
Baba, H | 1 |
Shirabe, K | 1 |
Kakeji, Y | 1 |
Hong, TS | 1 |
Ryan, DP | 1 |
Suenaga, M | 1 |
Mizunuma, N | 2 |
Matsusaka, S | 1 |
Shinozaki, E | 1 |
Ozaka, M | 1 |
Ogura, M | 1 |
Yamaguchi, T | 1 |
Pachman, DR | 1 |
Seisler, DK | 1 |
Smith, EM | 1 |
Beutler, AS | 1 |
Ta, LE | 1 |
Lafky, JM | 1 |
Wagner-Johnston, ND | 1 |
Ruddy, KJ | 1 |
Dakhil, S | 1 |
Staff, NP | 1 |
Shahriari-Ahmadi, A | 1 |
Fahimi, A | 1 |
Payandeh, M | 1 |
Sadeghi, M | 1 |
Kanai, M | 1 |
Kawaguchi, T | 1 |
Matsumoto, S | 1 |
Watanabe, T | 1 |
Matsuda, F | 1 |
Tsuruta, A | 1 |
Yamashita, K | 1 |
Tanioka, H | 1 |
Inukai, M | 1 |
Yamakawa, T | 1 |
Yamatsuji, T | 1 |
Yoshimitsu, M | 1 |
Toyota, K | 1 |
Yamano, T | 1 |
Nagasaka, T | 1 |
Okajima, M | 1 |
Tanishima, H | 1 |
Tominaga, T | 1 |
Kimura, M | 1 |
Maeda, T | 1 |
Shirai, Y | 1 |
Liu, ZF | 2 |
Guo, QS | 1 |
Zhang, XQ | 1 |
Yang, XG | 1 |
Guan, F | 1 |
Fu, Z | 1 |
Wang, MY | 2 |
Gu, Y | 1 |
Shu, Y | 1 |
Xu, Q | 1 |
Okada, N | 1 |
Miyazaki, T | 1 |
Sano, M | 1 |
Frye, DK | 1 |
Boehnke Michaud, L | 1 |
Michalaki, V | 1 |
Gennatas, S | 1 |
Gennatas, K | 1 |
Zhao, JG | 2 |
Qiu, F | 2 |
Xiong, JP | 2 |
Zhang, L | 2 |
Xiang, XJ | 2 |
Yu, F | 2 |
Yan, J | 2 |
Zhan, ZY | 2 |
Feng, M | 2 |
Milla, P | 1 |
Airoldi, M | 1 |
Weber, G | 1 |
Drescher, A | 1 |
Jaehde, U | 1 |
Cattel, L | 1 |
Truchuelo, M | 1 |
Vano-Galvan, S | 1 |
Pérez, B | 1 |
Muñoz-Zato, E | 1 |
Jaén, P | 1 |
Dong, NN | 1 |
Zhang, Q | 1 |
Sakakibara, T | 1 |
Matsuyoshi, K | 1 |
Yuki, K | 1 |
Yokota, M | 1 |
Itakura, Y | 1 |
Adachi, M | 1 |
Saito, H | 1 |
Matsunaga, Y | 1 |
Motokawa, S | 1 |
Nakagaki, S | 1 |
Yoshida, T | 1 |
Muramatsu, T | 1 |
Kimura, H | 1 |
Ohashi, Y | 1 |
Kudou, Y | 1 |
Shino, M | 1 |
Baena-Cañada, JM | 1 |
Martínez, MJ | 1 |
García-Olmedo, O | 1 |
Jiménez-Bárcenas, R | 1 |
Muriel-Cueto, P | 1 |
Storey, DJ | 1 |
Sakala, M | 1 |
McLean, CM | 1 |
Phillips, HA | 1 |
Dawson, LK | 1 |
Wall, LR | 1 |
Fallon, MT | 1 |
Clive, S | 1 |
Stein, A | 1 |
Wang, J | 1 |
Fan, Y | 1 |
Xu, B | 2 |
Sparano, JA | 2 |
Vrdoljak, E | 1 |
Rixe, O | 1 |
Manikhas, A | 1 |
Medina, C | 1 |
Da Costa, SC | 1 |
Ro, J | 1 |
Rubio, G | 1 |
Rondinon, M | 1 |
Perez Manga, G | 1 |
Peck, R | 1 |
Poulart, V | 1 |
Conte, P | 1 |
Kato, K | 1 |
Inaba, Y | 1 |
Esaki, T | 1 |
Yoshioka, A | 1 |
Mizuno, T | 1 |
Kusaba, H | 1 |
Fujii, H | 1 |
Shimada, Y | 2 |
Shirao, K | 2 |
Schønnemann, KR | 1 |
Yilmaz, M | 1 |
Andersen, M | 1 |
Pfeiffer, P | 2 |
Egerton, N | 1 |
Inada, M | 1 |
Sato, M | 1 |
Kitagawa, K | 1 |
Kawada, K | 1 |
Mitsuma, A | 1 |
Sawaki, M | 1 |
Fujita, K | 1 |
Ando, Y | 1 |
Arkenau, HK | 1 |
Nishioka, M | 1 |
Kurita, N | 1 |
Iwata, T | 1 |
Morimoto, S | 1 |
Yoshikawa, K | 1 |
Miyatani, T | 1 |
Shibata, M | 1 |
Shimura, T | 1 |
Nishina, Y | 1 |
Gonda, K | 1 |
Matsuo, S | 1 |
Abe, H | 1 |
Yajima, Y | 1 |
Nakamura, I | 1 |
Ohki, S | 1 |
Takenoshita, S | 1 |
Yi, SK | 1 |
Mak, W | 1 |
Yang, CC | 1 |
Liu, T | 1 |
Cui, J | 1 |
Chen, AM | 1 |
Purdy, JA | 1 |
Monjazeb, AM | 1 |
Do, L | 1 |
Vahdat, LT | 1 |
Thomas, ES | 1 |
Roché, HH | 1 |
Hortobagyi, GN | 1 |
Yelle, L | 1 |
Fornier, MN | 1 |
Martín, M | 1 |
Bunnell, CA | 1 |
Mukhopadhyay, P | 1 |
Peck, RA | 1 |
Perez, EA | 1 |
Alejandro, LM | 1 |
Behrendt, CE | 1 |
Chen, K | 1 |
Openshaw, H | 1 |
Shibata, S | 1 |
Hong, YS | 1 |
Lee, SS | 1 |
Kim, KP | 1 |
Lee, JL | 1 |
Kang, YK | 1 |
Shin, SJ | 1 |
Ahn, JB | 1 |
Jung, KH | 1 |
Im, SA | 1 |
Kim, TY | 2 |
Kim, JH | 1 |
Park, YS | 1 |
Kim, TW | 1 |
Vincenzi, B | 1 |
Frezza, AM | 1 |
Schiavon, G | 1 |
Spoto, C | 1 |
Silvestris, N | 1 |
Addeo, R | 1 |
Catalano, V | 1 |
Graziano, F | 1 |
Santini, D | 1 |
Tonini, G | 1 |
Tatsushima, Y | 1 |
Egashira, N | 1 |
Narishige, Y | 1 |
Fukui, S | 1 |
Kawashiri, T | 1 |
Yamauchi, Y | 1 |
Oishi, R | 1 |
Zhu, Y | 1 |
Yang, J | 1 |
Jiao, S | 1 |
Ji, T | 1 |
Twelves, C | 3 |
Lin, E | 1 |
Morris, JS | 1 |
Ayers, GD | 2 |
Videtic, GM | 1 |
Campbell, C | 1 |
Vincent, MD | 1 |
Goetz, MP | 1 |
Erlichman, C | 1 |
Windebank, AJ | 1 |
Reid, JM | 1 |
Sloan, JA | 1 |
Adjei, AA | 1 |
Rubin, J | 1 |
Pitot, H | 1 |
Galanis, E | 1 |
Ames, MM | 1 |
Goldberg, RM | 1 |
Scheithauer, W | 2 |
McKendrick, J | 1 |
Begbie, S | 1 |
Borner, M | 1 |
Burns, WI | 1 |
Burris, HA | 1 |
Jodrell, D | 1 |
Koralewski, P | 1 |
Levine, EL | 1 |
Marschner, N | 1 |
Maroun, J | 1 |
Garcia-Alfonso, P | 1 |
Tujakowski, J | 1 |
Van Hazel, G | 2 |
Wong, A | 1 |
Zaluski, J | 1 |
Hahn, P | 1 |
Jensen, HA | 1 |
Hildebrandt, B | 1 |
Dräger, J | 1 |
Kerner, T | 1 |
Deja, M | 1 |
Löffel, J | 1 |
Stroszczynski, C | 1 |
Ahlers, O | 1 |
Felix, R | 1 |
Riess, H | 1 |
Wust, P | 1 |
Kakolyris, S | 1 |
Souglakos, J | 1 |
Kouroussis, C | 1 |
Androulakis, N | 1 |
Samonis, G | 1 |
Vardakis, N | 1 |
Amarantidis, K | 1 |
Agelaki, S | 1 |
Mavroudis, D | 1 |
Xenidis, N | 1 |
Georgoulias, V | 1 |
Maindrault-Goebel, F | 1 |
Tournigand, C | 1 |
André, T | 1 |
Carola, E | 1 |
Mabro, M | 1 |
Artru, P | 1 |
Louvet, C | 1 |
de Gramont, A | 1 |
Lee, JJ | 1 |
Kim, TM | 1 |
Yu, SJ | 1 |
Kim, DW | 1 |
Joh, YH | 1 |
Oh, DY | 1 |
Kwon, JH | 1 |
Heo, DS | 1 |
Bang, YJ | 1 |
Kim, NK | 1 |
Saif, MW | 3 |
Wood, TE | 1 |
McGee, PJ | 1 |
Diasio, RB | 2 |
Lebowitz, PF | 1 |
Eng-Wong, J | 1 |
Swain, SM | 1 |
Berman, A | 1 |
Merino, MJ | 1 |
Chow, CK | 1 |
Venzon, D | 1 |
Zia, F | 1 |
Danforth, D | 1 |
Liu, E | 1 |
Zujewski, J | 1 |
Mattioli, R | 1 |
Massacesi, C | 1 |
Recchia, F | 1 |
Marcucci, F | 1 |
Cappelletti, C | 1 |
Imperatori, L | 1 |
Pilone, A | 1 |
Rocchi, M | 1 |
Cesta, A | 1 |
Laici, G | 1 |
Bonsignori, M | 1 |
Lippe, P | 1 |
Kopp, HG | 1 |
Moerike, K | 1 |
Kanz, L | 1 |
Hartmann, JT | 1 |
Lim, JF | 1 |
Tjandra, JJ | 1 |
Hiscock, R | 1 |
Chao, MW | 1 |
Gibbs, P | 1 |
Stathopoulos, GP | 2 |
Rigatos, SK | 1 |
Stathopoulos, JG | 1 |
Xynotroulas, JP | 1 |
Dimou, E | 1 |
Yamada, Y | 1 |
Miyata, Y | 1 |
Doi, T | 1 |
Muto, M | 1 |
Hamaguchi, T | 1 |
Mera, K | 1 |
Yano, T | 1 |
Tanigawara, Y | 1 |
Hildebrand, J | 1 |
Lin, EH | 1 |
Curley, SA | 1 |
Crane, CC | 1 |
Feig, B | 1 |
Skibber, J | 1 |
Delcos, M | 1 |
Vadhan, SR | 1 |
Morris, J | 1 |
Ross, A | 1 |
Brown, T | 1 |
Rodriguez-Bigas, MA | 1 |
Janjan, N | 1 |
Hashmi, S | 1 |
Mattison, L | 1 |
Donovan, WB | 1 |
Muto, O | 1 |
Ando, H | 1 |
Ono, T | 1 |
Itagaki, H | 1 |
Kobayashi, Y | 1 |
Onuki, M | 1 |
Akashi, T | 1 |
Tanaka, Y | 1 |
Hanaoka, T | 1 |
Land, SR | 1 |
Kopec, JA | 1 |
Cecchini, RS | 1 |
Ganz, PA | 1 |
Wieand, HS | 1 |
Colangelo, LH | 1 |
Murphy, K | 1 |
Kuebler, JP | 1 |
Seay, TE | 1 |
Needles, BM | 1 |
Bearden, JD | 1 |
Colman, LK | 1 |
Lanier, KS | 1 |
Pajon, ER | 1 |
Cella, D | 1 |
Smith, RE | 1 |
O'Connell, MJ | 2 |
Costantino, JP | 1 |
Wolmark, N | 1 |
Polychronopoulos, P | 1 |
Iconomou, G | 1 |
Koutras, A | 1 |
Makatsoris, T | 1 |
Gerolymos, MK | 1 |
Gourzis, P | 1 |
Assimakopoulos, K | 1 |
Chroni, E | 1 |
Fountzilas, G | 1 |
Dafni, U | 1 |
Gogas, H | 1 |
Linardou, H | 1 |
Briasoulis, E | 1 |
Pectasides, D | 1 |
Samantas, E | 1 |
Bafaloukos, D | 1 |
Karina, M | 1 |
Papadimitriou, C | 1 |
Skarlos, D | 1 |
Pisanidis, N | 1 |
Papakostas, P | 1 |
Markopoulos, C | 1 |
Tzorakoeleftherakis, E | 1 |
Dimitrakakis, K | 1 |
Makrantonakis, P | 1 |
Xiros, N | 1 |
Polichronis, A | 1 |
Varthalitis, I | 1 |
Karanikiotis, C | 1 |
Dimopoulos, AM | 1 |
Schmid, P | 1 |
Kühnhardt, D | 1 |
Kiewe, P | 1 |
Lehenbauer-Dehm, S | 1 |
Schippinger, W | 1 |
Greil, R | 1 |
Lange, W | 1 |
Preiss, J | 1 |
Niederle, N | 1 |
Brossart, P | 1 |
Freier, W | 1 |
Kümmel, S | 1 |
Van de Velde, H | 1 |
Regierer, A | 1 |
Possinger, K | 1 |
Werbrouck, BF | 1 |
Pauwels, WJ | 1 |
De Bleecker, JL | 1 |
Gruenberger, B | 1 |
Tamandl, D | 1 |
Schueller, J | 1 |
Zielinski, C | 1 |
Herbst, F | 1 |
Gruenberger, T | 1 |
Shindo, Y | 1 |
Tenma, K | 1 |
Imano, H | 1 |
Hibino, M | 1 |
Yoshino, K | 1 |
Herrmann, R | 1 |
Spehn, J | 1 |
Beyer, JH | 1 |
von Franqué, U | 1 |
Schmieder, A | 1 |
Holzmann, K | 1 |
Abel, U | 1 |
Buswell, L | 1 |
Recht, A | 1 |
Clark, J | 1 |
Ravikumar, T | 1 |
Busse, PM | 1 |
Coleman, CN | 1 |
Frasci, G | 1 |
Leone, F | 1 |
Monaco, M | 1 |
Cremone, L | 1 |
Sapio, U | 1 |
Faiella, F | 1 |
Espinosa, A | 1 |
Persico, G | 1 |
Gunderson, LL | 1 |
Nelson, H | 1 |
Martenson, JA | 1 |
Cha, S | 1 |
Haddock, M | 1 |
Devine, R | 1 |
Fieck, JM | 1 |
Wolff, B | 1 |
Dozois, R | 1 |
Lévi, F | 1 |
Zidani, R | 1 |
Misset, JL | 1 |
Soulié, P | 1 |
Raymond, E | 1 |
Brienza, S | 1 |
Cvitkovic, E | 1 |
Meropol, NJ | 1 |
Rustum, YM | 1 |
Creaven, PJ | 1 |
Blumenson, LE | 1 |
Frank, C | 1 |
Rosati, G | 1 |
Rossi, A | 1 |
Tucci, A | 1 |
Pizza, C | 1 |
Manzione, L | 1 |
Wilson, RH | 2 |
Harold, N | 1 |
Keith, B | 1 |
Dougherty, DS | 1 |
Grem, JL | 2 |
Oshaughnessy, JA | 1 |
Blum, J | 1 |
Moiseyenko, V | 2 |
Jones, SE | 1 |
Miles, D | 2 |
Bell, D | 1 |
Rosso, R | 1 |
Mauriac, L | 2 |
Osterwalder, B | 2 |
Burger, HU | 1 |
Laws, S | 1 |
Eckel, F | 1 |
Schmelz, R | 1 |
Adelsberger, H | 1 |
Erdmann, J | 1 |
Quasthoff, S | 1 |
Lersch, C | 1 |
Chang, DZ | 1 |
Olencki, T | 1 |
Budd, GT | 1 |
Peereboom, D | 1 |
Ganapathi, R | 1 |
Bukowski, R | 1 |
Lehky, T | 1 |
Thomas, RR | 1 |
Quinn, MG | 1 |
Floeter, MK | 1 |
O'Shaughnessy, J | 1 |
Vukelja, S | 1 |
Ayoub, JP | 1 |
Cervantes, G | 1 |
Fumoleau, P | 1 |
Jones, S | 1 |
Lui, WY | 1 |
Verma, S | 1 |
Leonard, R | 1 |
Carmo-Pereira, J | 1 |
Teles, AG | 1 |
Costa, FO | 1 |
Pimentel, P | 1 |
McCarthy, GM | 1 |
Skillings, JR | 1 |
Sebille, A | 1 |
St-Guily, JL | 1 |
Angelard, B | 1 |
de Stabenrath, A | 1 |
Fosså, SD | 1 |
Dahl, O | 1 |
Hoel, R | 1 |
Heier, M | 1 |
Loeb, M | 1 |
Legha, SS | 1 |
Dimery, IW | 1 |
Patt, YZ | 1 |
Peters, RE | 1 |
Chuang, VP | 1 |
Wallace, S | 1 |
Claghorn, L | 1 |
Mavligit, G | 1 |
Clinical Trials (28)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase 3, Randomized Study of Adjuvant Immunotherapy With Nivolumab Combined With Ipilimumab Versus Nivolumab Monotherapy After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma[NCT03068455] | Phase 3 | 1,844 participants (Actual) | Interventional | 2017-04-11 | Completed | ||
A Phase 2 Randomized Study Comparing the Efficacy and Safety of mFOLFOX6+Panitumumab Combination Therapy and 5-FU/LV+Panitumumab Combination Therapy in the Patients With Chemotherapy-Naive Unresectable Advanced Recurrent Colorectal Carcinoma of KRAS Wild-[NCT02337946] | Phase 2 | 164 participants (Actual) | Interventional | 2014-10-16 | Completed | ||
Temozolomide and Irinotecan Consolidation in Patients With MGMT Silenced, Microsatellite Stable Colorectal Cancer With Persistence of Minimal Residual Disease in Liquid Biopsy After Standard Adjuvant Chemotherapy: the ERASE-TMZ Study[NCT05031975] | Phase 2 | 35 participants (Anticipated) | Interventional | 2022-05-02 | Recruiting | ||
The Effect of Monosialotetrahexosylganglioside (GM1) in Prevention of Oxaliplatin Induced Neurotoxicity in Colorectal Cancer Patients Who Received Oxaliplatin-based Adjuvant Chemotherapy: A Multi-center, Randomized, Placebo-controlled Trial[NCT02251977] | Phase 3 | 196 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
Phase II Study of FOLFIRINOX Chemotherapy for Treatment of Advanced Gastric, Gastro-esophageal Junction, and Esophageal Tumors[NCT01928290] | Phase 2 | 67 participants (Actual) | Interventional | 2013-11-08 | Completed | ||
Survival Rate and Treatment Cost in Patients With Pancreatic Cancer With the Advent of New Chemotherapeutic Agents in Korea: An Analysis Using NHIS Database and K-PaC Registry Focusing on the Newest One, Liposomal Irinotecan[NCT04984174] | 54,000 participants (Anticipated) | Observational | 2021-08-04 | Recruiting | |||
Phase 2 Clinical Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer: a Multicenter Randomized Placebo-controlled Double-blind Study to Investigate the Efficacy and Safety of [NCT02792842] | Phase 2 | 79 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients[NCT05298670] | Phase 2 | 80 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | ||
Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients: a Prospective, Randomized, Sham-controlled, Double-blinded and Multicenter Study[NCT05798884] | 150 participants (Anticipated) | Interventional | 2023-05-31 | Not yet recruiting | |||
The Possible Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer[NCT05590117] | Early Phase 1 | 48 participants (Anticipated) | Interventional | 2022-10-11 | Enrolling by invitation | ||
A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium in Two Different Versions to Prevent Oxaliplatin-Induced Sensory Neurotoxicity[NCT01099449] | Phase 3 | 362 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
Comparison of High Tone Therapy and TENS Therapy in Chemotherapy-induced Polyneuropathy[NCT03978585] | 51 participants (Actual) | Interventional | 2019-09-03 | Completed | |||
A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity[NCT00316914] | Phase 3 | 104 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine: A Randomized Controlled Trial.[NCT05641246] | Phase 2 | 66 participants (Anticipated) | Interventional | 2022-12-08 | Active, not recruiting | ||
A Phase I Study of Oxaliplatin, CPT-11, 5-FU and Leucovorin in Patients With Solid Tumors[NCT00005068] | Phase 1 | 0 participants | Interventional | 2000-01-31 | Completed | ||
XELOX III. Capecitabine (Xeloda) in Combination With Oxaliplatin (Eloxatin) as First-line Treatment of Patients With Advanced or Metastatic Colorectal Cancer. A Randomized Phase II Study[NCT00212615] | Phase 2/Phase 3 | 116 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
A Pilot Trial of Sequential Primary (Neoadjuvant) Combination Chemotherapy With Docetaxel/Capecitabine (TX) and Doxorubicin/Cyclophosphamide (AC) in Primary Breast Cancer With Evaluation of Chemotherapy Effects on Gene Expression[NCT00005908] | Phase 2 | 30 participants (Actual) | Interventional | 2000-06-30 | Completed | ||
Effects of Different Treatment for Anorectal Function of Patients With Rectal Cancer: a Study Protocol for a Prospective, Observational, Controlled, Multicentre Study[NCT05671809] | 402 participants (Anticipated) | Observational [Patient Registry] | 2023-01-01 | Not yet recruiting | |||
Randomized Phase 2 Study Comparing Pathological Responses on Colorectal Cancer Metastases After Preoperative Treatment Combining Bevacizumab With FOLFOX or FOLFIRI[NCT01858649] | Phase 2 | 60 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
Randomised Phase 2 Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors[NCT01858662] | Phase 2 | 4 participants (Actual) | Interventional | 2014-01-31 | Terminated (stopped due to due to poor recrutment) | ||
Exploration of New Biologic Factors' Predictive Value , Especially Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab[NCT01405430] | 63 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
First Line Infusional 5-Fluorouracil, Folinic Acid and Oxaliplatin for Metastatic Colorectal Cancer or Loco-Regional Recurrency - Role of Chronomodulated Delivery Upon Survival - A Multicenter Randomized Phase III Trial[NCT00003287] | Phase 3 | 554 participants (Anticipated) | Interventional | 1998-03-31 | Completed | ||
Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
Pilot Study of Oxaliplatin in Combination With Capecitabine in Adult Cancer Patients[NCT00019773] | Phase 1 | 0 participants | Interventional | 1999-07-31 | Completed | ||
An Open-label Randomized Clinical Trial to Compare the Toxicities and Efficacy of Pharmacokinetically-guided and BSA Fixed Dosing Strategy of Docetaxel and Paclitaxel in Chinese Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, and Breast Cancer Patie[NCT01891123] | 300 participants (Anticipated) | Interventional | 2013-06-30 | Recruiting | |||
Dose Escalation of Xeloda or 5FU Continuous Infusion in Combination With Taxotere and Concurrent Once Weekly, Hypofractionated Chest Radiotherapy for Advanced Non Small Cell Lung Cancer: A Phase I/II Study[NCT00256841] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2005-09-30 | Withdrawn (stopped due to Lack of funding) | ||
A Randomized Phase III Study to Investigate the Efficacy and Safety of Docetaxel + Capecitabine vs. Vinorelbine + Capecitabine Followed by Capecitabine Alone as 1st Therapy on Locally Advanced and Metastatic Breast Cancer Patients.[NCT01126138] | Phase 3 | 200 participants (Anticipated) | Interventional | 2010-07-31 | Recruiting | ||
A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer[NCT01642771] | Phase 3 | 636 participants (Anticipated) | Interventional | 2012-06-30 | Active, not recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Overall Survival (OS) - All Randomized Participants
OS is defined as the time between the date of randomization and the date of death. Median based on Kaplan-Meier Estimates. (NCT03068455)
Timeframe: From randomization to date of death (up to approximately 45 months)
Intervention | Months (Median) |
---|---|
Arm A: Nivo + Ipi | NA |
Arm B: Nivo | NA |
Overall Survival (OS) - All Randomized Participants With PD-L1 Expression Level < 1%
OS is defined as the time between the date of randomization and the date of death. Median based on Kaplan-Meier Estimates. (NCT03068455)
Timeframe: From randomization to date of death (up to approximately 45 months)
Intervention | Months (Median) |
---|---|
Arm A: Nivo + Ipi | NA |
Arm B: Nivo | NA |
Progression-free Survival (PFS) on Next-line Therapy - All Randomized Participants
PFS2 was defined as the time from randomization to the progression date on next-line systemic therapy or the end date of next-line systemic therapy (if progression date not available) or death from any cause (if both progression date and end date not available), and to last known alive date in case of no event (ie, censoring), meaning either (1) no subsequent systemic therapy and no death OR (2) subsequent systemic therapy but no progression date nor end date available and no death. (NCT03068455)
Timeframe: From randomization to progression event (up to approximately 45 months)
Intervention | Months (Median) |
---|---|
Arm A: Nivo + Ipi | NA |
Arm B: Nivo | NA |
Progression-free Survival (PFS) on Next-line Therapy - All Randomized Participants With PD-L1 Expression Level < 1%
PFS2 was defined as the time from randomization to the progression date on next-line systemic therapy or the end date of next-line systemic therapy (if progression date not available) or death from any cause (if both progression date and end date not available), and to last known alive date in case of no event (ie, censoring), meaning either (1) no subsequent systemic therapy and no death OR (2) subsequent systemic therapy but no progression date nor end date available and no death. (NCT03068455)
Timeframe: From randomization to progression event (up to approximately 45 months)
Intervention | Months (Median) |
---|---|
Arm A: Nivo + Ipi | NA |
Arm B: Nivo | NA |
Recurrence-free Survival (RFS) - All Randomized Participants
"RFS was defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (from any cause), whichever occurred first.~Median values based on Kaplan-Meier Estimates." (NCT03068455)
Timeframe: From randomization to Primary Completion Date (up to approximately 3 years)
Intervention | Months (Median) |
---|---|
Arm A: Nivo + Ipi | NA |
Arm B: Nivo | NA |
Recurrence-free Survival (RFS) - All Randomized Participants With PD-L1 Expression Level < 1%
"RFS was defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (from any cause), whichever occurred first.~Median based on Kaplan-Meier Estimates." (NCT03068455)
Timeframe: From randomization to Primary Completion Date (up to approximately 3 years)
Intervention | Months (Median) |
---|---|
Arm A: Nivo + Ipi | 33.15 |
Arm B: Nivo | 27.63 |
Time From Next Therapy to Second Next Therapy - All Randomized Participants
Time from next treatment to second next treatment was defined as the time from the start date of next systemic therapy to start date of second next systemic therapy. No censoring rules were applied here as analysis was only performed for the subset of participants who received second next treatment. (NCT03068455)
Timeframe: From start of first next systemic therapy to start of second next systemic therapy (up to approximately 28 months)
Intervention | Months (Median) |
---|---|
Arm A: Nivo + Ipi | 4.60 |
Arm B: Nivo | 4.80 |
Time From Next Therapy to Second Next Therapy - All Randomized Participants With PD-L1 Expression Level < 1%
Time from next treatment to second next treatment was defined as the time from the start date of next systemic therapy to start date of second next systemic therapy. No censoring rules were applied here as analysis was only performed for the subset of participants who received second next treatment. (NCT03068455)
Timeframe: From start of first next systemic therapy to start of second next systemic therapy (up to approximately 28 months)
Intervention | Months (Median) |
---|---|
Arm A: Nivo + Ipi | 4.44 |
Arm B: Nivo | 5.04 |
Recurrence-free Survival (RFS) by Baseline Tumor PD-L1 Expression
"RFS was defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (from any cause), whichever occurred first.~Median based on Kaplan-Meier Estimates." (NCT03068455)
Timeframe: From randomization to Study Completion Date (up to approximately 45 months)
Intervention | Months (Median) | ||||
---|---|---|---|---|---|
< 1% Tumor PD-L1 Expression | ≥ 1% Tumor PD-L1 Expression | ≥ 5% Tumor PD-L1 Expression | < 5% Tumor PD-L1 Expression | Non-quantifiable Tumor PD-L1 Expression | |
Arm A: Nivo + Ipi | 33.18 | NA | NA | NA | NA |
Arm B: Nivo | 25.33 | NA | NA | NA | NA |
Time to Next-Line Therapies - All Randomized Participants
"Time to next therapy was defined as the time from the date of randomization to the start date of next systemic therapy. Participants who did not receive next treatment were censored at the last known alive date.~Time to second next therapy was defined as the time from the date of randomization to the start date of second next systemic therapy. Participants who did not receive second next treatment were censored at the last known alive date." (NCT03068455)
Timeframe: From randomization to start of next therapy or second next therapy (up to approximately 45 months)
Intervention | Months (Median) | |
---|---|---|
Time to next therapy | Time to second next therapy | |
Arm A: Nivo + Ipi | NA | NA |
Arm B: Nivo | NA | NA |
Time to Next-Line Therapies - All Randomized Participants With PD-L1 Expression Level < 1%
"Time to next therapy was defined as the time from the date of randomization to the start date of next systemic therapy. Participants who did not receive next treatment were censored at the last known alive date.~Time to second next therapy was defined as the time from the date of randomization to the start date of second next systemic therapy. Participants who did not receive second next treatment were censored at the last known alive date" (NCT03068455)
Timeframe: From randomization to start of next therapy or second next therapy (up to approximately 45 months)
Intervention | Months (Median) | |
---|---|---|
Time to next therapy | Time to second next therapy | |
Arm A: Nivo + Ipi | NA | NA |
Arm B: Nivo | NA | NA |
Overall Survival (OS)
OS was defined as the time from the day of randomization (Day 0) until death by all causes. (NCT02337946)
Timeframe: Up to approximately 31 months
Intervention | months (Median) |
---|---|
Group A | NA |
Group B | NA |
Percentage of Participants With Adverse Events
Safety population was defined as all participants who received at least one dose of protocol treatment after randomization. (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)
Intervention | percentage of participants (Number) |
---|---|
Group A | 100 |
Group B | 100 |
Percentage of Participants With Grade 2 or Higher Peripheral Neuropathy
"Peripheral neuropathy was defined as events classified with a preferred term (PT) of peripheral neuropathy according to Standardized MedDRA Queries." (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)
Intervention | percentage of participants (Number) |
---|---|
Group A | 30.4 |
Group B | 3.7 |
Progression-Free Survival (PFS)
The PFS is the period from the date of randomization (Day 0) until the date of judgment of progression from the date of randomization, or until death by all causes, whichever comes first. The presence/absence of progressive disease (PD) was determined based on imaging, consideration of clinical PD, or survival research results. PD based on response evaluation criteria in solid tumors (RECIST) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT02337946)
Timeframe: Up to approximately 31 months
Intervention | months (Median) |
---|---|
Group A | 9.1 |
Group B | 9.3 |
Progression-Free Survival Rate (PFS Rate) at 9 Months After Randomization
PFS rate was defined as the gross percentage of participants who survived with no evidence of progression from the day of randomization (Day 0) until 9 months after Day 0. The presence/absence of progressive disease (PD) was determined based on imaging, consideration of clinical PD, or survival research results. PD based on response evaluation criteria in solid tumors (RECIST) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT02337946)
Timeframe: Up to 9 months after randomization
Intervention | percentage of participants (Number) |
---|---|
Group A | 46.4 |
Group B | 47.4 |
Response Rate (RR)
RR was defined as the percentage of participants who had shown complete response (CR) or partial response (PR) as the best overall response in accordance with the RECIST 1.1 criteria after randomization. The best overall response was CR, followed by PR, stable disease (SD), progressive disease (PD), and not evaluable (NE). CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to <10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters as the best overall response after randomization., SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). (NCT02337946)
Timeframe: Up to approximately 31 months
Intervention | percentage of participants (Number) |
---|---|
Group A | 80.4 |
Group B | 87.7 |
Time to Treatment Failure (TTF)
TTF was defined as the time from the day of randomization (Day 0) until the day of protocol treatment discontinuation determination, the day of PD decision during protocol treatment, or death from any cause, whichever came the earliest. (NCT02337946)
Timeframe: Up to approximately 31 months
Intervention | months (Median) |
---|---|
Group A | 8.1 |
Group B | 6.1 |
Percentage of Participants With Adverse Events by Severity Graded Using the Common Terminology Criteria for Adverse Events (CTCAE) Grade
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)
Intervention | percentage of participants (Number) | ||
---|---|---|---|
Grade 1 | Grade 2 | Grade 3, 4 and 5 | |
Group A | 0 | 19.6 | 80.4 |
Group B | 0 | 27.8 | 72.2 |
Percentage of Participants With Grade 3 or Higher Skin Toxicity
"Skin toxicity was defined as events classified with an system organ class of Skin and subcutaneous tissue disorders or a preferred term of paronychia." (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)
Intervention | percentage of participants (Number) | |
---|---|---|
Skin and subcutaneous tissue disorders | Paronychia | |
Group A | 17.9 | 7.1 |
Group B | 18.5 | 9.3 |
Clinical Benefit Rate
"Clinical benefit rate is the percentage of combined patients who have achieved complete response (CR), partial response (PR), and stable disease (SD)~CR: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm~PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters~SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study." (NCT01928290)
Timeframe: Through completion of treatment (estimated to be 4 months)
Intervention | Participants (Count of Participants) |
---|---|
Arm A: FOLFIRINOX (HER2-negative) | 33 |
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 22 |
Duration of Response
Time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
Intervention | months (Median) |
---|---|
Arm A: FOLFIRINOX (HER2-negative) | 5.8 |
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 10.5 |
Number of Participants With an Objective Response
"Objective response (defined as complete response (CR) + partial response (PR) by RECIST 1.1 criteria)~CR: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.~PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters." (NCT01928290)
Timeframe: Through completion of treatment (estimated to be 4 months)
Intervention | Participants (Count of Participants) |
---|---|
Arm A: FOLFIRINOX (HER2-negative) | 25 |
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 22 |
Overall Survival (OS)
Overall survival is defined as the time interval from date of diagnosis to date of death from any cause. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
Intervention | months (Median) |
---|---|
Arm A: FOLFIRINOX (HER2-negative) | 15.5 |
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 19.6 |
Progression Free Survival
Duration of time from start of treatment to time of progression or death, whichever occurs first. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
Intervention | months (Median) |
---|---|
Arm A: FOLFIRINOX (HER2-negative) | 8.4 |
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 13.8 |
Time to Progression (TTP)
Duration of time from start of treatment to time of progression. Progression is defined as At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
Intervention | months (Median) |
---|---|
Arm A: FOLFIRINOX (HER2-negative) | 8.0 |
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 13.9 |
Toxicity and Tolerability (Arm A and Arm B) as Measured by the Number of Participants With Grade 3 or Higher Adverse Events
(NCT01928290)
Timeframe: 30 days after completion of treatment (estimated to be 5 months)
Intervention | participants (Number) | ||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anemia | Febrile neutropenia | Anal Fistula | Diarrhea | Hematemesis | Nausea | Peripheral ischemia | Vomiting | Fatigue | Laparoscopy surgery | Pain | Sepsis | Lung infection | Pneumonia | Hypernatremia | Neutrophil count decreased | Platelet count decreased | Anorexia | Dehydration | Hypokalemia | Back pain | Peripheral sensory neuropathy | Syncope | Dyspnea | Pleural embolism | Skin infection | Thromboembolic event | Abdominal pain | Enterocolitis | Hemorrhoids | G-tube infection | Neutropenic entercolitis | Alkaline phosphatase increased | |
Arm A: FOLFIRINOX (HER2-negative) | 1 | 2 | 1 | 4 | 1 | 2 | 1 | 3 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 19 | 3 | 3 | 4 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 0 | 0 | 0 | 5 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
Area Under the Curve (AUC) of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Chemotherapy-induced Peripheral Neuropathy (EORTC QLQ-CIPN20) Motor Neuropathy Subscale Scores
The oxaliplatin-induced motor neuropathy as repeatedly measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Chemotherapy-induced peripheral neuropathy (EORTC QLQ-CIPN20) motor neuropathy subscale during the chemotherapy. This is a multivariate repeated measurement of CIPN with possibly variable cycles for every patient. The CIPN motor neuropathy subscale will be calculated by standard scoring algorithm and converted to 0-100 scale, where higher scores represent a higher quality of life. Rather than choosing the CIPN20 motor neuropathy subscale at a fixed cycle of chemotherapy, we will adopt a summary measure, area under the curve (AUC) of CIPN20 motor neuropathy subscale as the endpoint. This AUC will be prorated by the number of chemotherapy cycles patients received. (NCT01099449)
Timeframe: Up to 18 Months
Intervention | AUC QLQ-CIPN20 Motor Neuropathy Score (Mean) |
---|---|
Calcium Gluconate + Magnesium Sulfate (Pre and Post) | 94.1 |
Placebo (Pre and Post) | 93.3 |
Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post) | 91.6 |
Area Under the Curve (AUC) of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Chemotherapy-induced Peripheral Neuropathy (EORTC QLQ-CIPN20) Autonomic Neuropathy Subscale Scores
The oxaliplatin-induced autonomic neuropathy as repeatedly measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Chemotherapy-induced peripheral neuropathy (EORTC QLQ-CIPN20) autonomic subscale during the chemotherapy. This is a multivariate repeated measurement of CIPN with possibly variable cycles for every patient. The CIPN autonomic subscale will be calculated by standard scoring algorithm and converted to 0-100 scale, where higher scores represent a higher quality of life. Rather than choosing the CIPN20 autonomic subscale at a fixed cycle of chemotherapy, we will adopt a summary measure, area under the curve (AUC) of CIPN20 autonomic subscale as the endpoint. This AUC will be prorated by the number of chemotherapy cycles patients received. (NCT01099449)
Timeframe: Up to 18 months
Intervention | score on a scale (Mean) |
---|---|
Calcium Gluconate + Magnesium Sulfate (Pre and Post) | 89.8 |
Placebo (Pre and Post) | 86.7 |
Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post) | 84.5 |
Cumulative Oxaliplatin Doses That Can be Administered Without Dose-limiting Chronic Neurotoxicity
A patient has a dose-limiting chronic neurotoxicity when they discontinue oxaliplatin-based chemotherapy because of neurotoxicity. (NCT01099449)
Timeframe: Up to 18 months
Intervention | Doses (Mean) |
---|---|
Calcium Gluconate + Magnesium Sulfate (Pre and Post) | 8.1 |
Placebo (Pre and Post) | 8.4 |
Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post) | 8.0 |
Incidence of Calcium Gluconate and Magnesium Sulfate-induced Adverse Events as Measured by CTCAE Version 4.0
(NCT01099449)
Timeframe: Up to 18 months
Intervention | Number of reported Adverse Events (Number) |
---|---|
Arm I | 290 |
Arm II | 259 |
Arm III | 296 |
Percentage of Patients Discontinuing Oxaliplatin-based Chemotherapy Because of Neurotoxicity
(NCT01099449)
Timeframe: Up to 18 months
Intervention | percentage of patients (Number) |
---|---|
Calcium Gluconate + Magnesium Sulfate (Pre and Post) | 34.7 |
Placebo (Pre and Post) | 27.7 |
Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post) | 30.5 |
Sensory Area Under the Curve(AUC) Score. Oxaliplatin-induced Sensory Neuropathy as Repeatedly Measured by the EORTC QLQ-CIPN20 Sensory Subscale During Chemotherapy
The oxaliplatin-induced sensory neuropathy as repeatedly measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Chemotherapy-induced peripheral neuropathy (EORTC QLQ-CIPN20) sensory subscale during the chemotherapy. This is a multivariate repeated measurement of CIPN with possibly variable cycles for every patient. The CIPN sensory subscale will be calculated by standard scoring algorithm and converted to 0-100 scale, where higher scores represent a higher quality of life. Rather than choosing the CIPN20 sensory subscale at a fixed cycle of chemotherapy, we will adopt a summary measure, area under the curve (AUC) of CIPN20 sensory subscale as the primary endpoint. This AUC will be prorated by the number of chemotherapy cycles patients received. (NCT01099449)
Timeframe: Up to 18 months
Intervention | score on a scale (Mean) |
---|---|
Calcium Gluconate + Magnesium Sulfate (Pre and Post) | 89.2 |
Placebo (Pre and Post) | 88.3 |
Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post) | 87.1 |
Area Under the Curve (AUC) of Patient-reported Quality of Life (QOL) as Measured by the Supplemental QOL Questionnaire
This is a multivariate repeated measurement of CIPN with possibly variable cycles for every patient. The supplemental quality of life (QOL) subscale will be calculated by standard scoring algorithm and converted to 0-100 scale, where higher scores represent a higher quality of life. Rather than choosing the subscale at a fixed cycle of chemotherapy, we will adopt a summary measure, area under the curve (AUC) . This AUC will be prorated by the number of chemotherapy cycles patients received. (NCT01099449)
Timeframe: Up to 18 months
Intervention | score on a scale (Mean) | ||||||
---|---|---|---|---|---|---|---|
Diarrhea | Constipation | Stomach Cramping | Bowel Problems | Swallowing | Numbness in finger and toes | Tingling in finger and toes | |
Arm I | 86.7 | 90.1 | 92.8 | 89.1 | 91.2 | 83.4 | 78.9 |
Arm II | 86.2 | 88.8 | 90.6 | 88.5 | 87.6 | 81.8 | 76.5 |
Arm III | 84.5 | 88.0 | 89.4 | 84.6 | 86.7 | 80.0 | 76.3 |
Percentage of Patients Experiencing Grade 2+ and Grade 3+ Chronic Cumulative Neurotoxicity.
Grades are determined by the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.0) and oxaliplatin-specific neurotoxicity scale, during and after chemotherapy. Higher grades symbolize greater severity of the adverse event. (NCT01099449)
Timeframe: Up to 18 months
Intervention | percentage of patients (Number) | |
---|---|---|
grade 2+ | grade 3+ | |
Calcium Gluconate + Magnesium Sulfate (Pre and Post) | 42.7 | 7.7 |
Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post) | 46.1 | 7.8 |
Placebo (Pre and Post) | 44.8 | 7.8 |
Percentage of Patients With Acute Neuropathy Associated With Oxaliplatin
This is the percent of patients who scored >=50 in all sequences of all cycles by arm for side effect Q1: Sensitivity to touching cold. This is a> repeated measurement of CIPN with possibly variable cycles for every patient. The CIPN subscale will be calculated by standard scoring algorithm and converted to 0-100 scale. Where 0 is no sensitivity and 100 is as bad as it can be. (NCT01099449)
Timeframe: Up to 18 months
Intervention | percentage of patients (Number) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Cycle 1 | Cycle 2 | Cycle 3 | Cycle 4 | Cycle 5 | Cycle 6 | Cycle 7 | Cycle 8 | Cycle 9 | Cycle 10 | Cycle 11 | Cycle 12 | |
Arm I | 10 | 24 | 32 | 34 | 34 | 31 | 35 | 32 | 34 | 29 | 28 | 27 |
Arm II | 13 | 27 | 33 | 37 | 33 | 37 | 34 | 34 | 37 | 39 | 39 | 45 |
Arm III | 14 | 28 | 32 | 36 | 39 | 33 | 34 | 33 | 32 | 30 | 33 | 32 |
Time to Onset of Grade 2+ and Grade 3+ Chronic Cumulative Neurotoxicity and the Duration of the Chronic Cumulative Neurotoxicity During and After Chemotherapy
Time to onset of grade 2+ and grade 3+ chronic cumulative neurotoxicity, the duration of the chronic cumulative neurotoxicity during and after the adjuvant oxaliplatin-based chemotherapy. Grades are determined by the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.0) and oxaliplatin-specific neurotoxicity scale, during and after chemotherapy. Higher grades symbolize greater severity of the adverse event. (NCT01099449)
Timeframe: Up to 18 months
Intervention | Days (Median) | |
---|---|---|
Time to Grade 2 Neuropathy | Time to Grade 3 Neuropathy | |
Calcium Gluconate + Magnesium Sulfate (Pre and Post) | 171 | NA |
Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post) | 171 | NA |
Placebo (Pre and Post) | 173 | 208 |
Average Duration of Chronic Neuropathic Toxicity
Neuropathic adverse events were assessed by CTCAE v3.0. (NCT00316914)
Timeframe: 127 days
Intervention | days (Median) |
---|---|
Ca/Mg | 81 |
Placebo | 72 |
Percentage of Patients Discontinuing Therapy for Chronic Neurotoxicity
Neurotoxicity were assessed by CTCAE v3.0. (NCT00316914)
Timeframe: 127 days
Intervention | Percentage of Participants (Number) |
---|---|
Ca/Mg | 46 |
Placebo | 55.8 |
Percentage of Patients With Acute Neuropathic Adverse Event
Acute neuropathic toxicities were measured using the Symptom Experience Diary and supplemental quality of life questions in the scale of 0 (no symptom) to 10 (worst symptom). The item score was reversed and transformed into 0 (low QOL) to 100 (best QOL) scale for analysis. Any score greater than 0 was considered having acute neuropathy. (NCT00316914)
Timeframe: 127 days
Intervention | Percentage of participants (Number) |
---|---|
Ca/Mg | 88 |
Placebo | 90 |
Percentage of Patients With Oxaliplatin-induced Grade 2+ Chronic Neuropathic Adverse Event
Neuropathic adverse events were assessed by Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Neurotoxicity evaluation grade: loss of deep tendon reflexes or paresthesia, including tingling, but not interfering with function (Grade 1); objective sensory alteration or paresthesia, including tingling, interfering with function, but not with activities of daily living (Grade 2); sensory alteration or paresthesia interfering with activities of daily living (Grade 3); permanent sensory losses that are disabling (Grade 4) (NCT00316914)
Timeframe: 127 days
Intervention | Percentage of participants (Number) |
---|---|
Ca/Mg | 22 |
Placebo | 41 |
Time to Onset of Grade 2+ Chronic Neurotoxicity
Neurotoxicity were assessed by Common Terminology Criteria for Adverse Events (CTCAE) v3.0. (NCT00316914)
Timeframe: 127 days
Intervention | Days (Median) |
---|---|
Ca/Mg | NA |
Placebo | 18.1 |
Time to Onset of Grade 3+ Chronic Neurotoxicity
Neurotoxicity was assessed by CTCAE v3.0. (NCT00316914)
Timeframe: 127 days
Intervention | Days (Median) |
---|---|
Ca/Mg | NA |
Placebo | NA |
Change From Baseline in Fatigue Score at One Month
Fatigue was measured by Brief Fatigue Inventory in the scale of 0 (no fatigue) to 10 (fatigue as bad as you can imagine). The item score was reversed and transformed into 0 (low quality of life (QOL)) to 100 (best QOL) scale for analysis. Change: score at one month minus score at baseline. (NCT00316914)
Timeframe: Baseline and One month
Intervention | units on a scale (Mean) | ||
---|---|---|---|
Fatigue NOW | Fatigue USUAL | Fatigue WORST | |
Ca/Mg | 1.0 | 3.1 | 0.0 |
Placebo | -2.8 | -1.6 | -1.6 |
Change From Baseline in Quality of Life (QOL) at One Month
Quality of Life (QOL) were measured using the Symptom Experience Diary and supplemental quality of life questions. Item score range: 0 (no symptom) to 10 (worst symptom). The score was reversed and transformed into 0 (low QOL) to 100 (best QOL) scale for analysis. Change: score at one month minus score at baseline. (NCT00316914)
Timeframe: Baseline and One month
Intervention | Units on a scale (Mean) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Fatigue WORST | Walking | Buttoning Shirt or Tying Laces | Diarrhea | Constipation | Abdominal Cramping | Bowel Problems with Normal Activity | Shortness of Breath (Week 2 - Baseline) | Swallowing (Week 2 - Baseline) | Numbness in Fingers, Toes (Week 2 - Baseline) | Tingling in Fingers, Toes (Week 2 - Baseline) | |
Ca/Mg | 0.0 | -2.5 | -2.0 | -7.1 | -2.9 | -2.5 | -3.2 | -0.7 | -7.5 | -8.3 | -14.8 |
Placebo | -1.6 | 0.2 | 0.4 | -10.4 | 0.4 | 1.3 | -9.1 | 2.1 | 2.1 | -9.6 | -20.4 |
Incidence of Calcium Magnesium (CaMg)-Induced Adverse Event
Adverse Events were measured using CTCAE V3.0. (NCT00316914)
Timeframe: 127 days
Intervention | Percentage of Participants (Number) | |||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abdominal Infection | Acne NOS | Anemia | Anorexia | Clostridial Infection | Constipation | Dehydration | Diarrhea-No Colostom | Dry Skin | Erythema Multiforme | Fatigue | Hypercalcemia | Hyperglycemia | Hypermagnesemia | Hypersensitivity | Hypokalemia | Hypomagnesemia | Hyponatremia | Infection | Ischemia-Cerebral | Ischemia/Infarction | Laryngeal Discomfort | Leukopenia | Muscle Weakness | Myalgia | Nausea | Neuro-motor | Neuro-sensory | Neutropenia | Oral cavity MS CE | Pain-Abdominal | Pain-Chest | Pain-Headache | Rash/Desquamation | Skin Rxn-Hand/Foot | Stomatitis | Taste | Thrombocytopenia | Thrombosis | Urticaria | Vasc Access Complication | Vomiting | |
Ca/Mg | 2 | 2 | 4 | 4 | 0 | 42 | 2 | 68 | 0 | 4 | 10 | 0 | 2 | 14 | 6 | 4 | 0 | 4 | 0 | 0 | 2 | 0 | 6 | 2 | 4 | 60 | 4 | 2 | 18 | 2 | 0 | 0 | 0 | 4 | 4 | 2 | 2 | 2 | 6 | 0 | 2 | 34 |
Placebo | 0 | 2 | 4 | 2 | 2 | 47 | 6 | 73 | 2 | 0 | 25 | 2 | 0 | 18 | 0 | 2 | 2 | 0 | 2 | 2 | 0 | 2 | 10 | 0 | 0 | 71 | 4 | 12 | 33 | 0 | 8 | 2 | 4 | 0 | 2 | 2 | 2 | 2 | 4 | 2 | 0 | 33 |
Number of Participants With Adverse Events
Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00005908)
Timeframe: 6 years
Intervention | Participants (Number) |
---|---|
Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine | 9 |
Dose B-Cohort 2-Arm 2 Reduced Dose-Docetaxel & Capecitabine | 20 |
Complementary Deoxyribonucleic Acid (cDNA) Expression
Patients were classified as responders or non-responders based on change in tumor size by clinical exam and pathologic response.For instance, patients with a pathological complete response, micro-invasive disease at surgery, or clinical complete response after four cycles of treatment were considered responders. Changes in gene expression associated with treatment was assessed before/after chemotherapy. All gene expression summary intensities below 50 were thresholded to the value of 50 and genes showing variability significantly smaller than the median gene variability were screened out. (NCT00005908)
Timeframe: 6 years
Intervention | Participants (Number) | |
---|---|---|
Responders | Non-responders | |
Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine | 8 | 2 |
Dose B-Cohort 2-Arm 2 Reduced Dose-Docetaxel & Capecitabine | 7 | 13 |
Number of Participants, e.g. Responders and Non-responders With a Percent Change in Expression Patterns After Chemotherapy With Changes in Expression Patterns After Chemotherapy in Preclinical Models
Patients were classified as responders or non-responders based on change in tumor size by clinical exam and pathologic response.For instance, patients with a pathological complete response, micro-invasive disease at surgery, or clinical complete response after four cycles of treatment were considered responders. Changes in gene expression associated with treatment was assessed before/after chemotherapy. All gene expression summary intensities below 50 were thresholded to the value of 50 and genes showing variability significantly smaller than the median gene variability were screened out. (NCT00005908)
Timeframe: 6 years
Intervention | Participants (Number) | |
---|---|---|
Responders | Non-responders | |
Dose A & B-Cohort 1 & 2-Arm 1 & 2-Docetaxel & Capecitabine | 8 | 13 |
Overall Clinical Response Rate
Overall response rate is defined as the percentage of participants with a CR (complete disappearance of all target lesions), PR (a 30% decrease in the sum of the longest diameter of target lesions) determined by clinical measurements per the Response Evaluation Criteria in Solid Tumors (RECIST) and/or a complete pathologic response (disappearance of all invasive tumor pathologically or presence of ductal carcinoma in situ) per the Chevallier criteria. For details about the RECIST or Chevallier criteria see the protocol link module. (NCT00005908)
Timeframe: 6 years
Intervention | Percentage of participants (Number) | ||
---|---|---|---|
Complete Response | Partial Response | Complete pathologic response | |
Dose A & B-Cohort 1 & 2-Arm 1& 2-Docetaxel & Capecitabine | 31 | 59 | 10 |
Reviews
10 reviews available for fluorouracil and Peripheral Nervous System Diseases
Article | Year |
---|---|
Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal | 2018 |
A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2014 |
Capecitabine-based combination therapy for breast cancer: implications for nurses.
Topics: Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marr | 2009 |
The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabin | 2009 |
Interaction between capecitabine and brivudin in a patient with breast cancer.
Topics: Aged; Anemia, Aplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 2010 |
Ixabepilone.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabi | 2010 |
Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2010 |
Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer?
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials | 2002 |
Neurological complications of cancer chemotherapy.
Topics: Antineoplastic Agents; Capecitabine; Central Nervous System; Deoxycytidine; Fluorouracil; Humans; Ma | 2006 |
[Oxaliplatin: the first DACH platinum in clinical practice].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; | 1997 |
Trials
59 trials available for fluorouracil and Peripheral Nervous System Diseases
Article | Year |
---|---|
Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neopla | 2022 |
SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2019 |
JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2019 |
Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Disease-F | 2020 |
Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecit | 2020 |
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Esophageal Ne | 2020 |
Protective effect of the oral administration of cystine and theanine on oxaliplatin-induced peripheral neuropathy: a pilot randomized trial.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cy | 2020 |
A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 2020 |
Efficacy of Exercise Rehabilitation Program in Relieving Oxaliplatin Induced Peripheral Neurotoxicity.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Digestiv | 2021 |
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2018 |
Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Egypt; Fluorouracil; Humans; L | 2018 |
Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Egypt; Fluorouracil; Humans; L | 2018 |
Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Egypt; Fluorouracil; Humans; L | 2018 |
Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Egypt; Fluorouracil; Humans; L | 2018 |
L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; | 2019 |
Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of Ch
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemother | 2013 |
Negative-balance isolated pelvic perfusion in patients with incurable symptomatic rectal cancer: results and drug dose correlation to adverse events.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ca | 2014 |
Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2013 |
Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance).
Topics: Administration, Intravenous; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium; Cold Tem | 2014 |
Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Double-Blind Method; Dru | 2015 |
Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemo | 2015 |
Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Calcium Compounds; Chronic Disease; C | 2015 |
Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2016 |
Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedul | 2008 |
A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; C | 2009 |
Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcino | 2009 |
A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progre | 2009 |
Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chemotherapy | 2009 |
[Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2009 |
Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Ne | 2010 |
Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capec | 2010 |
A multicenter phase-II study of 5-FU, leucovorin and oxaliplatin (FOLFOX6) in patients with pretreated metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2011 |
The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drugs | 2011 |
A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine | 2012 |
A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Co | 2013 |
Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Sched | 2003 |
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; | 2003 |
Whole-body hyperthermia in the scope of von Ardenne's systemic cancer multistep therapy (sCMT) combined with chemotherapy in patients with metastatic colorectal cancer: a phase I/II study.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 2004 |
Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Cap | 2004 |
Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne | 2004 |
Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic C | 2004 |
A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2004 |
High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2005 |
Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Respo | 2006 |
Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival?
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combi | 2006 |
Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 2007 |
Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colonic Neoplasms; Electrophys | 2007 |
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci | 2008 |
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Ne | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Combined-modality therapy of esophageal cancer with radiotherapy, etanidazole, and cisplatin-fluorouracil, with or without surgery: neurotoxicity, other toxicities and outcome.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1994 |
5-Fluorouracil-interferon-alpha 2b adjuvant treatment of Dukes C colorectal cancer.
Topics: Aged; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Colonic Neoplasms; Confidence | 1994 |
Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Colorectal Neoplasms; Fe | 1997 |
Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Cohort Studies; Diarr | 1999 |
Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Dose-Response | 2001 |
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combi | 2001 |
Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chr | 2001 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Phase II study of combination cytotoxic chemotherapy in advanced breast cancer: 2 years' followup.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Dr | 1976 |
Other Studies
61 other studies available for fluorouracil and Peripheral Nervous System Diseases
Article | Year |
---|---|
Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients.
Topics: Aged; Analgesics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bic | 2021 |
Incidence and risk factors associated with development of oxalipatin-induced acute peripheral neuropathy in colorectal cancer patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorou | 2023 |
Does statin suppress oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer? A single-center observational study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neo | 2023 |
Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Colorectal Neoplasms; Female; F | 2019 |
Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: A cross-sectional study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cross-Sectional Studies; Femal | 2020 |
Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2020 |
[Three Cases of Augmented Chemotherapy-Induced Peripheral Neuropathy after Changing from mFOLFOX6 to FOLFIRI Therapy in Patients with Colorectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2020 |
FLOX (5-fluorouracil + leucovorin + oxaliplatin) chemotherapy for colorectal cancer leads to long-term orofacial neurotoxicity: a STROBE-guided longitudinal prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2020 |
Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cross- | 2020 |
Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fema | 2021 |
The updated five-year overall survival and long-term oxaliplatin-related neurotoxicity assessment of the FACOS study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ad | 2021 |
Effect of a Shortened Duration of FOLFOX Chemotherapy on the Survival Rate of Patients with Stage II and III Colon Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-Free Survival; Drug | 2018 |
Prospective Study of the Clinical, Electrophysiologic, and Sonographic Characteristics of Oxaliplatin-Induced Neuropathy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Male; Middle Age | 2019 |
Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother | 2019 |
Effect of diabetes on neurological adverse effects and chemotherapy induced peripheral neuropathy in advanced colorectal cancer patients treated with different FOLFOX regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2019 |
Optimal duration of adjuvant therapy for stage III colon cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Chem | 2019 |
[A case with multiple liver metastases from rectal cancer responding completely to FOLFOX for a long duration without exacerbation of peripheral neuropathy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Fluorouracil; Humans; Leucovorin; Live | 2013 |
Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxyc | 2013 |
Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients.
Topics: Aged; Analgesics, Opioid; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dela | 2014 |
Incidence of cold-induced peripheral neuropathy and dose modification of adjuvant oxaliplatin-based chemotherapy for patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cold Temperatu | 2014 |
Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; C | 2015 |
A case of delayed oxaliplatin-induced pseudo-obstruction: an atypical presentation of oxaliplatin neurotoxicity.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colecto | 2015 |
Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Co | 2014 |
Adjuvant Chemotherapy for Locally Advanced Rectal Cancer: Is It a Given?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2015 |
Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran.
Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Cape | 2015 |
Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2016 |
Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chronic Disease | 2017 |
[Changes in peripheral neuropathy and platinum concentrations in patients undergoing surgery following modified FOLFOX6 therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Erythrocyte | 2008 |
Unilateral taxane-induced onychopathy in a patient with a brain metastasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antine | 2009 |
[Multicenter investigation of preventive measures against FOLFOX-induced neurotoxicity-a project of the 4th Chapter of the Oncology Research Group, Aichi Prefectural Society of Hospital Pharmacists].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2009 |
[Revision of the informed consent form for patients based on investigation of adverse events of mFOLFOX6 regimen].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2009 |
Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorourac | 2010 |
New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; De | 2011 |
Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; DNA-Bi | 2010 |
Capecitabine combined with oxaliplatin (CAPOX) in clinical practice: how significant is peripheral neuropathy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; O | 2011 |
[PSK decreased FOLFOX4-induced peripheral neuropathy and bone marrow suppression in patients with metastatic colorectal cancer].
Topics: Agaricales; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Co | 2011 |
Development of a standardized method for contouring the lumbosacral plexus: a preliminary dosimetric analysis of this organ at risk among 15 patients treated with intensity-modulated radiotherapy for lower gastrointestinal cancers and the incidence of rad
Topics: Anatomic Landmarks; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Fluorouracil; Hu | 2012 |
Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Tria | 2012 |
Predicting acute and persistent neuropathy associated with oxaliplatin.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cohort | 2013 |
Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV.
Topics: Age Factors; Aged; Alcohol Drinking; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, A | 2013 |
Calcium channel blockers reduce oxaliplatin-induced acute neuropathy: a retrospective study of 69 male patients receiving modified FOLFOX6 therapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calci | 2013 |
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capecitabine; Celecoxib; Colorectal Neoplasms; | 2002 |
Primary chemoradiation as definitive treatment for unresectable cancer of the trachea.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2003 |
Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2003 |
Peripheral neuropathy associated with capecitabine.
Topics: Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); | 2004 |
Leflunomide and peripheral neuropathy: a potential interaction between uracil/tegafur and leflunomide.
Topics: Administration, Oral; Aged; Arthritis, Rheumatoid; Comorbidity; Disease Progression; Drug Administra | 2005 |
Preoperative chemoradiation for rectal cancer causes prolonged pudendal nerve terminal motor latency.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biopsy; Female; Fluorouracil; Follow-U | 2006 |
Peripheral neuropathy exacerbation associated with topical 5-fluorouracil.
Topics: Aged; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Deh | 2006 |
[Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcium; Colorectal Neoplas | 2007 |
A case of 5-fluorouracil-induced peripheral neuropathy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Electromyography; Female; Fluorouracil; Humans; Low | 2008 |
[Reduction of oxaliplatin-related neurotoxicity by Gosha-jinki-gan].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2008 |
Sequential methotrexate and 5-fluorouracil: improved response rate in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Colonic Neoplasms; Drug | 1984 |
Locally advanced primary colorectal cancer: intraoperative electron and external beam irradiation +/- 5-FU.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modalit | 1997 |
Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Colonic Neoplasms; Dihydrouracil | 2001 |
[Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2002 |
Acute oxaliplatin-induced peripheral nerve hyperexcitability.
Topics: Acute Disease; Aged; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2002 |
Orofacial complications of chemotherapy for breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Candidiasis, Oral; Chi-Squa | 1992 |
Low prevalence of cisplatin-induced neuropathy after 4-day continuous infusion in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; El | 1990 |
Doxifluridine (5'-dFUrd) in patients with advanced colorectal carcinoma. A phase II study.
Topics: Angina Pectoris; Brain Diseases; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Evaluation; Elect | 1985 |
High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Squamo | 1985 |
Palliation of pelvic recurrence of colorectal cancer with intra-arterial 5-fluorouracil and mitomycin.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; C | 1985 |